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provide vital information on its involvement in the devel-
opment and pathogenesis of disease. Such knowledge will 
enable determination of which critical molecular pathways 
should be targeted by potential therapeutic agents devel-
oped for the treatment of tauopathies.
Keywords Tau · Microtubule binding · Alzheimer’s 
disease · Tauopathy · Synaptic dysfunction · Propagation
Introduction
It is estimated that more than 45 million people worldwide 
are living with dementia and this number is expected to 
increase to more than 130 million people by 2050 (http://
www.alz.co.uk/research/world-report-2016). Alzheimer’s 
disease (AD) is by far the most common form of demen-
tia; being more prevalent than vascular dementia, mixed 
dementia, Lewy body dementia (LBD) and frontotemporal 
dementia (FTD). In addition, other diseases clinically clas-
sified as primary motor disorders such as progressive supra-
nuclear palsy (PSP) and Parkinson’s disease (PD), also pre-
sent symptoms of cognitive decline and dementia. A key 
neuropathological characteristic common to these diseases 
is the presence in the brain of deposits of the microtubule-
associated protein tau, in various morphologies, which is 
apparent many years before the onset of clinical symptoms 
[154]. To date there are no effective, disease-modifying 
treatments available for tauopathies, and therefore, under-
standing the physiological and pathological roles of tau in 
health and disease is important to identify new therapeutic 
targets. This review summarises current knowledge of the 
wide range of roles for tau in health and disease, extending 
beyond its well-known functions in microtubule binding 
and stabilisation.
Abstract Tau is well established as a microtubule-asso-
ciated protein in neurons. However, under pathological 
conditions, aberrant assembly of tau into insoluble aggre-
gates is accompanied by synaptic dysfunction and neural 
cell death in a range of neurodegenerative disorders, col-
lectively referred to as tauopathies. Recent advances in our 
understanding of the multiple functions and different loca-
tions of tau inside and outside neurons have revealed novel 
insights into its importance in a diverse range of molecu-
lar pathways including cell signalling, synaptic plasticity, 
and regulation of genomic stability. The present review 
describes the physiological and pathophysiological proper-
ties of tau and how these relate to its distribution and func-
tions in neurons. We highlight the post-translational modifi-
cations of tau, which are pivotal in defining and modulating 
tau localisation and its roles in health and disease. We 
include discussion of other pathologically relevant changes 
in tau, including mutation and aggregation, and how these 
aspects impinge on the propensity of tau to propagate, and 
potentially drive neuronal loss, in diseased brain. Finally, 
we describe the cascade of pathological events that may be 
driven by tau dysfunction, including impaired axonal trans-
port, alterations in synapse and mitochondrial function, 
activation of the unfolded protein response and defective 
protein degradation. It is important to fully understand the 
range of neuronal functions attributed to tau, since this will 
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Tau structure and function
The tau gene and tau isoforms
Human tau is encoded by the MAPT gene, located on 
chromosome 17 [14]. The MAPT gene comprises 16 
exons, although exons 0 and 14 are transcribed but not 
translated. MAPT pre-RNA is differentially spliced in a 
manner correlating with stages of neuronal maturation 
and neuronal types [511]. In the human CNS, tau pro-
tein is translated from a 6-kb mRNA transcript gener-
ating a series of six tau protein isoforms of 37–46 kDa 
which result from alternative splicing of exons 2, 3, and 
10 (Fig. 1). These tau isoforms exhibit reduced mobility 
on sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis (SDS-PAGE), such that their apparent molecu-
lar weights do not correspond to their actual molecular 
weights (Fig. 1). MAPT exons 2 and 3 each encode an 
insert of 29 amino acids in the amino terminal region of 
tau, and exon 3 is not transcribed in the absence of exon 
2. Exons 4A, 6 and 8 are transcribed exclusively in the 
peripheral nervous system, from a 9-kb MAPT transcript, 
which is translated into a series of larger tau proteins of 
110–120 kDa. Exons 9–12 encode four highly conserved 
imperfect repeats of 30–31 amino acids that comprise the 
microtubule binding domain of tau; the second repeat 
being encoded by exon 10. Consequently, alternative 
splicing yields six tau isoforms that can be differentiated 
by the presence of zero, one or two N-terminal inserts 
(0N, 1N, or 2N, respectively), and the presence of either 
three (3R) or four (4R) microtubule binding repeats in the 
C-terminal half of tau (Fig. 1).
Tau expression is developmentally regulated, such that in 
the adult human brain, all six isoforms of tau are expressed 
in the CNS, whereas in foetal brain, only the shortest tau 
isoform (0N3R) is expressed [164]. Approximately equal 
amounts of the 3R and 4R tau isoforms are present in the 
cerebral cortex of healthy adults [164]. Differential splic-
ing of exons 2 and 3 results in 2N tau isoforms being rela-
tively under-represented in comparison to 0N and 1N tau 
such that 0N, 1N, and 2N tau comprise 37, 54 and 9% of 
total human CNS tau, respectively [160]. However, the pro-
portions of each tau isoform varies between species and in 
adult mouse brain, the three isoforms of 4R tau are almost 
exclusively expressed [260]. Furthermore, murine 3R tau 
isoforms are only transiently expressed in the neurons of 
foetal and new-born mice [306]. There are also regional 
differences in splicing of the MAPT gene in brain. For 
example, in humans, the amount of 0N3R tau is lower in 
the cerebellum than it is in other brain regions and 4R tau 
isoforms are increased in the globus pallidus [43, 329].
The structural basis of tau binding to its interacting 
partners
The structure of tau is important for its normal functions. 
The amino acid sequence of the longest human CNS tau 
isoform (2N4R, 441 amino acids) contains a low propor-
tion of hydrophobic amino acids relative to other proteins, 
rendering tau an overall hydrophilic protein [25]. The 
Four-repeat (4R) tau isoforms
Three-repeat (3R) tau isoforms
2N3R
1N3R
0N3R
2N4R
1N4R
0N4R
N PRD MTBD C Actual MW
45,850 67,000
App. MW
N PRD MTBD C Actual MW App. MW
42,967 59,000
40,007 52,000
42,603 62,000
39,720 54,000
36,760 48,000
Fig. 1  Tau protein domains and alternative splicing in the human 
CNS. Six isoforms of tau are generated in the human CNS by alter-
native splicing of the MAPT gene. Distinct amino acid sequences 
encoded by exons 2 and 3 in the N-terminal region of tau are either 
excluded (0N), or differentially included giving rise to 1N (exon 2) 
or 2N (exons 2 and 3) tau isoforms. The central region of tau com-
prises the proline-rich domain (PRD). Alternative splicing of exon 10 
in the microtubule binding domain (MTBD), results in 3R or 4R tau 
isoforms. The C-terminal region is common to all six human CNS tau 
isoforms. The actual molecular weight (MW, kDa), and the apparent 
(App.) MW of each tau isoform on SDS-PAGE, are indicated on the 
right
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tau molecule can be subdivided into four major domains, 
which are distinguished by their biochemical properties 
(Fig. 1). The N-terminal acidic projection domain (amino 
acids 1–150) contains two distinct alternatively spliced 
N-terminal inserts. The region of tau that encompasses 
residues 151–243 (the proline-rich domain) [321]. The 
microtubule binding domain consists of four imperfectly 
repeated motifs, separated by flanking regions, which 
together provide the primary structures by which tau binds 
and stabilises microtubules. In contrast to the majority of 
the tau molecule, the second and third microtubule bind-
ing domain repeats exhibit a propensity to form an ordered 
β-sheet structure [354]. Finally, amino acids 370–441 form 
the C-terminal tail of tau.
Biophysical studies have revealed tau to be a natively 
unfolded protein, which maintains a highly flexible confor-
mation and overall has a low content of secondary structure 
[231, 354]. However, this apparent lack of well-defined 
secondary structure does not preclude tau folding through 
intramolecular interactions between its differently charged 
domains. Additionally, X-ray scattering, Fourier transform 
infrared spectroscopy, circular dichroism, and fluorescence 
spectroscopy also point to localised folding of tau [230]. 
Indeed, a “paperclip” conformation of tau has been pro-
posed (Fig. 2), within which the C terminus folds over the 
microtubule binding domain and the N terminus folds back 
over the C terminus, bringing both termini in close proxim-
ity [230]. Notably, this association between the N terminus 
and the C terminus of tau is reduced upon tau binding to 
microtubules (Fig. 2) [408]. Moreover, tau conformation 
is readily disrupted by proline-directed tau phosphoryla-
tion which variably results in loosening and tightening of 
the paperclip structure, and this may be dependent on the 
specific sites of tau phosphorylation [284]. Approximately 
26% of the residues in the 2N4R tau sequence are charged 
amino acids with a slight preponderance of positively 
charged residues, giving tau an overall basic character.
The N-terminal domain of tau projects away from 
microtubules (Fig. 2), and although this region of tau does 
not bind to microtubules directly, it is involved in regulat-
ing microtubule dynamics, influencing the attachment and/
or spacing between microtubules and other cell components 
[71]. For example, N-terminally truncated tau fragments 
showed altered microtubule interactions, even in the pres-
ence of an intact microtubule binding domain [327]. The 
extreme N-terminal region of tau (residues 2–18) has been 
shown to be involved in a signalling cascade that inhibits 
axonal transport in neurons [242]. The specific functions of 
the N-terminal inserts in tau are not yet well established, 
although these sequences appear to influence the distribu-
tion of tau because 0N, 1N, and 2N tau isoforms each show 
distinct subcellular localisations in mouse brain [295]. 
Similarly, removal of the N terminus (1–150 residues) of 
tau promotes its localisation to the nucleus in primary rat 
neurons and in a human neuroblastoma cell line [381]. It 
has also been proposed that tau interacts with components 
of the neural plasma membrane through its N-terminal 
domain, presumably via an interaction with the membrane-
binding protein annexin A2 [50, 154]. The N-terminal 
region of tau also binds to the C terminus of the p150 subu-
nit of the dynactin complex, which mediates the association 
of the microtubule motor dynein with membranous cargoes 
[317]. In addition, tau isoforms in possession of different 
numbers of N-terminal inserts display distinct protein inter-
action patterns. For example, apolipoprotein A1 preferen-
tially, if not exclusively, binds to 2N tau isoforms, whereas 
β-synuclein and synaptophysin more readily interact with 
0N tau isoforms [296].
The proline-rich domain of tau harbours seven Pro-X-
X-Pro (PXXP) motifs, providing potential recognition sites 
for Src homology-3 (SH3)-containing proteins including 
the Src family of protein kinases, such as Lck, Fgr, and Fyn, 
and other diverse proteins including bridging integrator 1 
(Bin1), peptidylprolyl cis/trans isomerases, NIMA-inter-
acting 1, the p85α regulatory subunit of phosphatidylino-
sitol 3-kinase (PI3K), phospholipase C (PLC) γ1, PLCγ2, 
and growth factor receptor bound protein 2 (Table 1) [352]. 
Direct interactions between tau and SH3-containing pro-
teins have been reported [36, 273, 278, 411, 462, 483] and 
these interactions are likely to have roles in modulating the 
Tau bound to microtubules
Tau free in cytoplasm
N
C
N
C
Fig. 2  Binding of tau to microtubules. Tau associates with microtu-
bules primarily through the microtubule binding domain, comprising 
either three or four repeats. The N and C termini of tau are closely 
associated when tau is free in the cytoplasm giving rise to the pro-
posed “paper-clip” model of tau conformation. On binding to micro-
tubules, the terminal regions of tau become separated and the N ter-
minus of tau projects away from the microtubule surface
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signalling functions of tau. Additionally, signalling roles 
have been postulated from the identification of phosphati-
dylinositol and phosphatidylinositol bisphosphate as tau 
binding partners of the proline-rich domain [134, 468]. 
Importantly, since proline-rich regions in proteins are the 
target of several other protein-interacting motifs, such as 
WW and Enabled/VASP homology 1 (EVH1) domains, 
tau has significant potential to modulate signal transduc-
tion [248]. Furthermore, the proline-rich domain of tau has 
also been identified as a DNA and RNA interacting site 
[403, 507], which may be related to the identification of 
tau in the nucleus [54]. The proline-rich domain of tau is 
also involved in regulation of microtubule assembly [121, 
169] and actin binding [196], indicating that this region of 
tau has important roles in neuronal cell signalling, nuclear 
function and maintenance of the neuronal cytoskeleton.
Interactions between tau and microtubules are medi-
ated by the microtubule binding repeats, while the flanking 
sequences that separate the repeats play a regulatory role in 
this interaction [355, 454]. Differing amino acid sequences 
between the four imperfect microtubule binding repeats in 
tau likely account for their differential affinities for micro-
tubules [368]. Additional proteins that interact with the 
microtubule binding region of tau include F-actin [88], 
α-synuclein [233], histone deacetylase 6 (HDAC6) [114], 
apolipoprotein E [212], and presenilin 1 [470] (Table 1). 
Binding of filamentous actin occurs through a minimum of 
two microtubule binding repeats in tau, enabling it to link 
to both actin and microtubules through the repeat domain, 
and thereby providing an important molecular tether 
between the actin and microtubule cytoskeletons [123]. 
Such a function for tau may be important for the mainte-
nance of healthy synapses and could therefore be critical 
during development, as well as in the tauopathies, particu-
larly since this association could be disrupted by increased 
tau phosphorylation [143, 341]. The microtubule binding 
domain of tau has also been shown to associate with lipid 
membranes and to bind to both DNA and RNA [156, 403, 
507].
Regions of tau located in both its proline-rich and micro-
tubule binding domains are responsible for its interaction 
with number of neurodegenerative disease-associated pro-
teins, including α-synuclein, 14-3-3, FUS, and TIA1 [184, 
194, 488]. These findings support the view that tau is likely 
to have important pathological roles in disorders in which 
these signature proteins are deposited in the brain [194, 
233].
Regarding the C-terminal region of tau, neither its func-
tion nor the proteins that bind to this domain, have been 
well established. However, a few studies have suggested 
that changes within this region might influence other 
domains of tau, including their interactions with other pro-
teins and their availability for phosphorylation [86, 411].Ta
bl
e 
1 
 
co
n
tin
ue
d
Cy
to
sk
el
et
al
N
uc
le
ar
Si
gn
al
lin
g
Sy
na
pt
ic
 re
gu
la
-
tio
n
Se
rin
e/
th
re
on
in
e-
pr
ot
ei
n 
ki
na
se
s
Ty
ro
sin
e 
ki
na
se
s
Pr
ot
ei
n 
ph
os
-
ph
at
as
es
O
th
er
 ta
u 
m
od
i-
fy
in
g 
en
zy
m
es
Pr
ot
eo
st
as
is
Li
pi
d 
re
la
te
d
Pr
ot
ei
n 
ki
na
se
 
C 
an
d 
ca
se
in
 
ki
na
se
 su
bs
tra
te
 
in
 n
eu
ro
ns
 
pr
ot
ei
n 
1
Le
uc
in
e-
ric
h 
re
pe
at
 se
rin
e/
th
re
on
in
e-
pr
o-
te
in
 k
in
as
e 
2
Se
rin
e 
pr
ot
ea
se
 
H
TR
A
1
α
/β
-
Tu
bu
lin
M
ito
ge
n-
ac
ti-
v
at
ed
 p
ro
te
in
 
ki
na
se
s
Pr
ot
ei
n 
ki
na
se
 C
 
fa
m
ily
Se
rin
e/
th
re
on
in
e-
pr
ot
ei
n 
ki
na
se
 
Sg
k1
Se
rin
e/
th
re
on
in
e-
pr
ot
ei
n 
ki
na
se
s 
TA
O
1/
2
Th
e 
ta
bl
e 
in
cl
ud
es
 a
 su
m
m
ar
y 
of
 th
e 
m
ajo
r ta
u b
ind
ing
 pa
rtn
ers
, g
rou
pe
d b
y t
he
ir f
un
cti
on
 or
 in
tra
cel
lul
ar 
loc
ali
sat
ion
. P
rot
ein
 n
am
es
 a
re
 li
ste
d 
in
 th
e 
U
ni
pr
ot
K
B 
da
ta
ba
se
 (h
ttp
://
w
w
w.
u
n
ip
ro
t.
o
rg
/u
ni
pr
ot
/),
 w
ith
 th
e e
x
ce
pt
io
n 
of
 so
m
e 
fa
m
ili
es
 o
f s
er
in
e/
th
re
on
in
e 
ki
na
se
s a
nd
 p
ro
te
in
 p
ho
sp
ha
ta
se
s [
19
,
 
32
3,
 
50
5]
670 Acta Neuropathol (2017) 133:665–704
1 3
Post‑translational modification of tau
Tau is subject to a wide range of post-translational modi-
fications, including phosphorylation, isomerisation, glyca-
tion, nitration, addition of β-linked N-acetylglucosamine 
(O-GlcNAcylation), acetylation, oxidation, polyamination, 
sumoylation, and ubiquitylation (reviewed in [323, 351]) 
(Fig. 3). Hence, many different tau binding partners share 
the property of being regulatory components of post-trans-
lational modification, such as protein kinases and phos-
phatases. Tau is also a substrate for the ubiquitin–protea-
some system (UPS) and for chaperone-mediated autophagy 
[416].
Tau phosphorylation
Phosphorylation is the most commonly described post-
translational tau modification. Tau contains 85 putative 
phosphorylation sites, including 45 serine, 35 threonine, 
and five tyrosine residues, which comprise 53, 41, and 6% 
of the phosphorylatable residues on tau, respectively [188]. 
Given the large number of potential phosphorylation sites 
on tau, it is not surprising that phosphorylation has a pro-
found impact on its physiological function. Under patho-
logical conditions, tau phosphorylation is increased, which 
reduces its affinity for microtubules, resulting in cytoskel-
eton destabilisation, particularly in neurons. Tau phospho-
rylation at Ser262, Ser293, Ser324 and Ser356, located in 
equivalent positions in each of the four microtubule bind-
ing repeats, decreases tau binding to microtubules [118]. 
In vitro studies have shown that phosphorylation at Thr214, 
Thr231 and Ser235 also contributes to the dissociation of 
tau from microtubules [266, 442]. These findings indicate 
that regions of tau lying outside the microtubule bind-
ing domain also influence the association of tau with the 
cytoskeleton.
There is a long-established link between abnormal 
phosphorylation and self-aggregation of tau. Tau phospho-
rylation decreases tau binding to microtubules and reduces 
microtubule stability. The detached tau then undergoes self-
aggregation, forming oligomers and higher order tau aggre-
gates [239, 498]. It is not yet known which of the many tau 
phosphorylation sites that have been identified are essen-
tial for disease pathogenesis and which sites may become 
phosphorylated only after the formation of tau pathology in 
the tauopathies. Mimicking permanent tau phosphorylation 
by substituting phosphorylatable residues with negatively 
charged glutamate or aspartate (pseudophosphorylation or 
phosphomimicking), reproduces some of the structural and 
functional aspects of the pathologically phosphorylated tau 
observed in AD brain and exerts neurotoxic effects, includ-
ing caspase activation and initiation of apoptosis [167]. 
Tau phosphorylation in the proline-rich region disrupts its 
microtubule assembly activity and induces a subtle increase 
in the propensity of tau to self-aggregate [121]. In contrast, 
phosphorylation of the C-terminal region of tau markedly 
promotes tau self-aggregation [300]. These reports suggest 
that site-specific tau phosphorylation serves to differentially 
regulate both microtubule binding and tau aggregation.
Several lines of evidence indicate that increased tau 
phosphorylation might induce neurodegeneration through 
mechanisms other than loss of microtubule binding func-
tion or gain of toxic oligomeric or aggregated tau spe-
cies. First, elevated tau phosphorylation detaches tau from 
microtubules and also induces tau missorting from axons 
into the somatodendritic compartment, compromising 
axonal microtubule integrity and inducing synaptic dys-
function [205, 226]. Second, phosphorylation of tau can 
disrupt its intracellular route of degradation. For example, 
tau phosphorylated on Ser262 or Ser356 is not recognised 
by the C terminus of heat shock protein 70-interacting 
protein-heat shock protein 90 (CHIP-HSP90) complex and 
Fig. 3  Post-translational 
modifications of tau. Illustra-
tion of the post-translational 
modifications identified on tau. 
The coloured bars indicate the 
approximate sites of each modi-
fication on the largest human 
CNS tau isoform (2N4R, 441 
amino acids)
Acetylation
Sumoylation
Glycation
Phosphorylation
Nitration
Ubiquitination
Methylation
Glycosylation
Polyamination
Isomerisation
Oxidation
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is thereby protected from degradation by the proteasome 
[111]. In contrast, phosphomimic tau is selectively cleared 
by autophagy compared to endogenous tau [416]. Third, 
microinjection of tau into synaptic terminals increases cal-
cium and disrupts synaptic transmission through a mecha-
nism involving kinase activation [347]. Finally, phospho-
rylation alters the association of tau with its interacting 
partners, such as cytoplasmic membrane, DNA and Fyn, 
disturbing the functions of tau in a range of signalling 
pathways [188]. However, recent evidence has suggested a 
protective role for tau phosphorylation against Aβ-induced 
toxicity [224]. In an AD mouse model generated based in 
APP23 mice, which expresses APP with both the Swed-
ish and London (V717I) mutations, specific tau phospho-
rylation at Thr205 disrupted the assembly of PSD-95/tau/
Fyn complexes, a complex required to mediate Aβ toxicity 
[224, 226].
Tau kinases
Tau phosphorylation is tightly controlled by the balance 
between protein kinases and phosphatases [188]. Tau 
kinases can be classed into three broad groups: (1) proline-
directed serine/threonine-protein kinases, including glyco-
gen synthase kinase (GSK) 3α/β, cyclin-dependent kinase-5 
(Cdk5), mitogen-activated protein kinases (MAPKs), and 
several other kinases including those activated by stress; 
(2) non-proline-directed serine/threonine-protein kinases, 
such as tau-tubulin kinase 1/2 (TTBK1/2), casein kinase 1 
(CK1), dual-specificity tyrosine phosphorylation regulated 
kinase 1A (DYRK1A), microtubule affinity-regulating 
kinases (MARKs), Akt/protein kinase B, cAMP-dependent 
protein kinase A (PKA), protein kinase C, protein kinase 
N, 5′ adenosine monophosphate-activated protein kinase 
(AMPK), calcium/calmodulin-dependent protein kinase 
II (CaMKII), and thousand and one amino acid protein 
kinases (TAOKs) 1 and 2, and (3) protein kinases specific 
for tyrosine residues, such as Src, Fyn, Abl, and Syk [323].
More than 40 putative phosphorylation sites in tau have 
been identified as targets of GSK3, with at least 29 of these 
residues being phosphorylated in AD brain [188]. Both the 
total protein amount and the activity of GSK3 in tauopa-
thy brain appears to correlate with the progression of neu-
rodegeneration, and over-activation of GSK3β significantly 
contributes to tau phosphorylation [386]. Moreover, GSK3 
activity correlates with neurofibrillary tangle burden in AD 
[284] and GSK3β colocalises with neurofibrillary pathol-
ogy in AD brain [191]. Tau phosphorylation by GSK3β has 
also been shown to induce tau aggregation [406]. GSK3β 
phosphorylates tau at Thr231 and primes residues in the C 
terminus of tau for subsequent phosphorylation, thereby 
providing a potential mechanism through which patho-
logical tau phosphorylation and aggregation occurs [75]. In 
transgenic mice, inhibiting GSK3β reduces tau phosphoryl-
ation, tau pathology development, axonal degeneration [57, 
283, 370], and rescues neuronal loss [444]. Taken together, 
these data suggest that inhibition of GSK3β could be a 
promising therapeutic strategy for AD. However, clinical 
trials of GSK3 inhibitors have not shown positive results 
and it is unclear whether targeting specific mediators of tau 
phosphorylation will provide an effective therapy for the 
tauopathies [370].
In addition to GSK3, other kinases such as Cdk5, 
p38MAPK, CK1δ, PKA, DYRK1A, and TAOKs may be 
involved in tangle formation in the tauopathies. For exam-
ple, an association between Cdk5, tau phosphorylation and 
neurofibrillary degeneration has been established in trans-
genic mice with aberrant Cdk5 activity [95, 371]. Several 
MAPKs phosphorylate tau and some colocalise with tan-
gles in AD brain [541]. CK1δ may also be an important 
candidate tau kinase since it phosphorylates tau on 46 sites 
[189] and colocalises with tau pathology in AD brain [440]. 
DYRK1A phosphorylates tau on three sites and inhibit-
ing DYRK1A has recently been proposed as a therapeutic 
approach for AD [91]. Notably, the ability of DYRK1A 
to phosphorylate Thr212 on tau, implicates DYRK1A as 
a potential priming kinase, facilitating subsequent GSK3β 
phosphorylation of tau on the nearby residue Ser208 [426]. 
Similar to GSK3, TAOKs 1 and 2 each phosphorylate tau 
on more than 40 residues, and have many overlapping sites 
[474]. Also, activated TAOKs colocalise with tangles, sug-
gesting a potential role for these kinases in the development 
of tau pathology in AD brain [474].
Tau is phosphorylated on five tyrosine residues at 
Tyr18, Tyr29, Tyr197, Tyr310, and Tyr394 [110, 274, 436]. 
A number of these tyrosine residues are also phosphoryl-
ated by Src family kinases, such as Src, Lck, Syk, Fyn 
and c-Abl [110, 411]. Phosphorylation of Tyr18, a site tar-
geted by Fyn kinase, has been proposed to regulate axonal 
transport [93, 241]. The tyrosine phosphorylation state of 
tau also appears to correlate with its propensity to aggre-
gate [188, 490]. Tyrosine phosphorylation of tau at Tyr18 
has also been detected in soluble and detergent-insoluble 
preparations of FTD brain and in spinal cord from mice 
expressing human tau with the P301L mutation, which is 
one of the many tau mutations responsible for the devel-
opment of frontotemporal lobar degeneration characterised 
by tau-positive inclusions (FTLD-tau) [490]. Interestingly, 
Tyr18 phosphorylation appears to have diverse effects in 
different neurodegenerative conditions. Tyr18 phospho-
rylation of tau occurs concurrently with an increase in 
phosphorylation at the AT8 epitope, an established marker 
of tau pathology, in transgenic mice expressing P301L 
tau, but not in 3xTg-AD mice, or in AD brain, in which 
β-amyloid (Aβ) deposition occurs alongside tau pathology 
[35, 277]. These findings imply that the role of tau tyrosine 
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phosphorylation might vary between different diseases. In 
addition, phosphorylation of tau at Tyr18 is required for 
Aβ-induced cell cycle re-entry, another pathological effect 
that could be involved in the process leading to neuronal 
cell death [446]. A key role for the interaction of tau with 
tyrosine kinases was demonstrated in mice overexpressing 
amyloid precursor protein (APP), which exhibit a signifi-
cantly increased Aβ load, and in which tau was shown to 
mediate Aβ-induced excitotoxicity through its interaction 
with Fyn tyrosine kinase [226].
Tau phosphatases
Protein phosphatase 2A (PP2A) accounts for more than 
70% of cellular phosphatase activity in the brain [297]. 
PP2A dephosphorylates tau and is implicated in the regu-
lation of tau phosphorylation [168]. PP2A activity is 
decreased by approximately 50% in AD brain, which could 
contribute to increased tau phosphorylation [297]. Incuba-
tion of misfolded tau isolated from AD brains with PP2A 
restores tau binding to microtubules to a level similar to 
that of recombinant 2N4R tau [504]. Another protein phos-
phatase, PP5, also dephosphorylates tau and its activity is 
reduced by 20% in AD brain [299]. It is worth mentioning 
that, in some cases, PP2A activity can override the kinase 
activities of GSK3β and Cdk5 with respect to tau [394]. 
These findings indicate that both down-regulation of tau 
dephosphorylation and excess phosphorylation of tau are 
implicated in the aberrant phosphorylation of tau observed 
in tauopathy brain.
PP2A has been reported to dephosphorylate GSK3β at 
Ser9 [281], and conversely, activation of GSK3β can inhibit 
PP2A [529]. Importantly, Akt inhibits GSK3β and hence 
plays a critical role in maintaining the balance between 
the activities of GSK3β and PP2A [94]. Thus, attenuation 
of PI3 K/Akt signalling, such as has been reported in AD 
brain, increases GSK3β activity and elevates tau phospho-
rylation and tangle formation. The mammalian target of 
rapamycin (mTOR) also regulates the activity of PP2A, 
since inhibiting mTOR results in PP2A activation [334]. 
These findings suggest the existence of a regulatory loop 
involving PP2A, mTOR, Akt, and GSK3β, which serves to 
maintain the phosphorylation status of tau. Hence, when 
Akt/mTOR signalling is adversely affected, this signalling 
pathway may also become perturbed, with consequences 
for tau phosphorylation and function [334].
Tau acetylation
Acetylation of tau is emerging as an important post-
translational modification relevant to both its physiologi-
cal and pathological functions [511]. Tau acetylation is 
mediated by cAMP-response element binding protein 
(CREB)-binding protein (CBP) [340], whereas sirtuin 1 
(SIRT1) and HDAC6 are responsible for tau deacetylation 
[87]. Notably, tau also has an intrinsic acetyltransferase 
activity, catalysing auto-acetylation mediated by cysteine 
residues 291 and 322, located within the second (R2) and 
third (R3) microtubule binding repeats of tau, respectively 
(Fig. 1) [83]. Studies examining the isolated microtubule 
binding domains of tau have suggested that this auto-acet-
ylation is dependent on the close proximity of the target 
lysines located at residues 274 and 340 [315]. Further-
more, auto-acetylation of tau facilitates the fragmentation 
of tau and possibly enhances its autophagic degradation 
[82]. CBP acetylates tau at several lysine residues within 
the microtubule binding repeats and the proline-rich region, 
whereas auto-acetylation occurs preferentially at lysine 
residues located in the microtubule binding repeats [82]. 
Acetylation of tau lysine residues 259, 290, 321 and 353 
occurs in control human brain, and appears to both pro-
tect tau from increased phosphorylation and suppress tau 
aggregation [87]. Conversely, acetylation of these lysine 
residues is reduced in AD brain and that of rTg4510 trans-
genic mice, that regulatably over-express FTLD-causing, 
P301L tau [87]. Acetylation of tau at lysines 174, 274 and 
280 has been detected in post-mortem AD, Pick’s disease 
(PiD), FTLD-tau, and PSP brain, and acetylation at these 
sites may be pathological [221, 339]. This view is sup-
ported by the observation that acetylation of lysines 163, 
280, 281 and 369 inhibits proteasome-mediated tau degra-
dation, leading to the accumulation of highly phosphoryl-
ated tau [84, 340, 351]. Acetylation of tau at Lys280 in par-
ticular appears to retard tau turnover, which may be critical 
for tau-induced toxicity [339, 481]. Furthermore, aberrant 
acetylation of tau at Lys274 and Lys280 has been detected 
in brain tissue from rTg4510 mice [461, 481]. Interestingly, 
acetylation of tau at Lys274 has been widely observed 
across the majority of human tauopathies, with the excep-
tion of the 4R tauopathy, argyrophilic grain disease (AGD) 
[178].
Mutant constructs that either mimic or block tau acety-
lation by substitution of specific Lys residues with Gln or 
Arg, respectively, have provided powerful tools with which 
to examine the role of tau acetylation in neurodegeneration. 
In a Drosophila transgenic model, mimicking tau acetyla-
tion at Lys280 exacerbated neurotoxicity caused by tau 
overexpression, and altered tau phosphorylation, resulting 
in locomotor defects and photoreceptor neurodegeneration 
without altering tau solubility [171]. Importantly, tau acety-
lation also impacts upon synaptic function. Mice express-
ing pseudo-acetylated (lysine substituted with glutamine) 
human tau at Lys274 and Lys281 (K274/281Q) display 
memory deficits and impaired hippocampal long-term 
potentiation (LTP) [481]. Such synaptic dysfunction has 
been attributed to reduced amounts of the memory-related 
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protein KIdney/BRAin (KIBRA) in transgenic mouse 
and AD brain [481], as well as to disruptions in activity-
induced post-synaptic actin remodelling and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptor membrane insertion [197]. Tau acetylation is 
also associated with destabilisation of the axon initial seg-
ment (AIS), which separates the soma and dendrites from 
the axon in neurons [458]. In primary neuronal cultures, 
expression of the tau acetylation mimic, K274/281Q, com-
promised the cytoskeletal network in the AIS, leading to 
the missorting of axonal K274/281Q tau into the somato-
dendritic compartment. In AD brain, reduced ankyrin and 
β-spectrin, which are components of the AIS, correlates 
with increased tau acetylation at Lys274 and Lys281 [458]. 
These findings suggest that pathological increases in acety-
lated tau destabilise the cytoskeletal network, resulting in 
tau mislocalisation in the somatodendritic compartment. 
Accumulation of acetylated tau in dendrites could disrupt 
the expression of KIBRA and AMPA receptor membrane 
insertion, leading to synaptic dysfunction and ultimately 
cognitive impairment.
These findings raise important questions about the 
means by which pathological tau acetylation is triggered, 
and how this modification impacts on synaptic function and 
the development of tau pathology in human disease. It is 
intriguing to speculate that the impact of tau acetylation on 
its function may be either beneficial or detrimental depend-
ing on the target residue and on the relative contributions of 
enzyme-mediated acetylation and auto-acetylation of tau. 
Since tau acetylation markedly influences the capacity of 
tau to become phosphorylated and aggregated, developing 
strategies to correct tau acetylation could represent a new 
therapeutic approach for the treatment of human tauopathy.
Other tau modifications
In human AD brain, but not in control brain, tau is modi-
fied by N-glycosylation, which is proposed to be involved 
in maintenance of the structure of neurofibrillary tan-
gles [503]. Furthermore, N-glycosylation may facilitate 
tau phosphorylation, by suppressing dephosphorylation 
to accelerate tau phosphorylation, most likely by affect-
ing tau conformation [301]. The mechanisms leading to 
N-glycosylation of tau in AD is unclear, however, it is 
feasible that alterations in the localisation of tau could 
result in aberrant glycosylation, which could affect tau 
function by increasing its phosphorylation.
In contrast, addition of O-linked N-acetylglucosamine 
(O-GlcNAc), which occurs on serine and threonine resi-
dues in tau, may protect it from phosphorylation, since 
this modification has been proposed to compete with 
tau kinases to modify the same target amino acids [298, 
457]. In addition, O-GlcNAcylation can suppress tau 
aggregation [531], and hence, the reduction in tau O-Glc-
NAcylation observed in AD brain might contribute to the 
increased phosphorylation and aggregation of tau [298]. 
Recently, it has been shown that O-GlcNAc transferase, 
the enzyme responsible for O-GlcNAcylation, is sig-
nificantly reduced in AD brain [502]. Moreover, mice in 
which expression of O-GlcNAc transferase was knocked 
out in forebrain exhibit cognitive impairment, along 
with neurodegeneration and increased tau phosphoryla-
tion [502], suggesting that targeting of O-GlcNAcyla-
tion might represent an effective therapeutic strategy for 
tauopathy.
Other types of post-translational modifications, includ-
ing glycation, deamidation and isomerisation, have also 
been detected in tau extracted from AD but not from con-
trol brain [515]. All of these modifications may facilitate 
tau aggregation, potentially by altering tau conformation 
[275, 515]. Furthermore, glycation of tau may reduce the 
binding of tau to microtubules [410].
Abnormal nitration of Tyr18, Tyr29 and Tyr394 in tau 
has been detected only in AD and other tauopathies. Nitra-
tion of these residues alters the conformation of tau, reduc-
ing its ability to bind to microtubules, and depending on the 
nitration sites can either promote or inhibit tau aggregation 
[410].
Notably, tau is ubiquitylated through Lys48 linkages by 
the action of CHIP or tumour necrosis factor receptor-asso-
ciated factor 6 (TRAF6), leading to proteasomal degrada-
tion of tau [392]. Increased tau ubiquitination also occurs 
in tauopathies. Interestingly, a competition between acety-
lation and ubiquitination of specific lysines in tau has been 
suggested in neurons, HEK293 cells and also in wild-type 
mice [340, 351]. Notably, 11 of the 14 acetylation sites 
identified in wild-type mice are also sites of ubiquitination 
in tau, suggesting that ubiquitination-dependent tau degra-
dation could be directly affected by tau acetylation [351]. 
Tau is also a substrate for sumoylation, with Lys340 being 
the major target site [313]. Sumoylation of tau by small 
ubiquitin-like modifier protein 1 (SUMO-1) counteracts 
the effects of ubiquitylation and correlates with increased 
tau phosphorylation, at least in cultured cells [313]. Moreo-
ver, in AD brain, SUMO-1 colocalises with phosphorylated 
tau [313]. Hence, it is likely that sumoylation promotes tau 
phosphorylation and inhibits ubiquitin-mediated tau degra-
dation, which could also contribute to the development of 
tau pathology in the tauopathies.
Finally, methylation of tau on both lysine and arginine 
residues has recently been described [144]. Although the 
functional implications of tau methylation have not been 
established, tau methylation occurs on many of the same 
lysine residues as does acetylation and ubiquitination [527]. 
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It is conceivable that lysine methylation within the Lys-X-
Gly-Ser (KXGS) motifs in the microtubule binding domain 
could reduce the ability of tau to bind and stabilise micro-
tubules, and potentially also modulate tau aggregation. In 
addition, some lysine sites are both mono-methylation and 
di-methylation recognition sites and the specific modifica-
tion would result in recognition by different methyl-bind-
ing domain proteins.
Collectively, there are at least four potentially competing 
modifications of tau that occur on lysine residues (glyca-
tion, acetylation, ubiquitination, and methylation), which 
highlights the strategic role of lysine modification in tau 
function.
In summary, there are a wide variety of post-translational 
modifications that can be present on tau in both physiologi-
cal and pathological states, as well as many different sites 
that can be affected by these alterations. This combination 
of factors makes it difficult to identify the most important 
pathways that modify tau and how these might be differen-
tially affected in health and disease.
Tau localisation in neurons
Under physiological conditions, tau in human brain is 
expressed in neurons and to a lesser extent in oligo-
dendrocytes and astrocytes [356, 383]. Intraneuronal 
tau is mainly located in axons [352] and in much lower 
amounts in somatodendritic compartments [473], includ-
ing the plasma membrane, nucleus and mitochondria 
[290] (Fig. 4). Several possible mechanisms have been 
proposed to contribute to the polarised distribution of tau 
within neurons. First, tau mRNA is specifically targeted 
to the axonal compartment by the axonal localisation sig-
nal sited within the 3′-untranslated region of the MAPT 
gene [21]. Following the transport of MAPT mRNA into 
the axon, tau translation can be specifically upregulated, 
due to the presence of a 5′-terminal oligopyrimidine tract 
which is recognised by the mechanistic target of rapam-
ycin-p70S6 kinase (mTOR-p70S6 K) pathway [349]. In 
addition, cytosolic tau can translocate to axons, either 
through free diffusion between the cytosol of different 
compartments or by motor protein-driven tau transport 
[258]. Tau molecules can also diffuse along microtubules 
guided by the microtubule lattice [201]. Alternatively, 
tau can be actively transported by motor proteins such as 
kinesin family members [484, 485]. Retention of tau in 
the axon is ensured by (1) maintaining a relatively low 
level of tau phosphorylation in axons, which increases its 
binding to axonal microtubules and (2) a functional axon 
initial segment, which forms a retrograde barrier, allow-
ing tau to enter the axon but preventing it from travelling 
back towards the soma and dendrites [289].
Cytoskeletal localisation of tau
In adult neurons, tau is mainly distributed in axons, where 
it interacts with microtubules. Upon binding, tau stabilises 
microtubules either directly, or through acting as a cross 
bridge which enables microtubules to interconnect with 
other cytoskeletal components such as actin and neurofila-
ments [1].
Tau can also serve as a direct inhibitor of HDAC6, 
which deacetylates tubulin, and inhibiting HDAC6 may 
thereby enhance microtubule stability [388]. However, 
reports are discordant on the amount of acetylated tubulin 
present in tau knockout mice, with some suggesting that 
tubulin acetylation is increased following tau deletion and 
others reporting no change in acetylated tubulin between 
tau knockout mice and wild-type controls [388, 408]. Thus, 
tau can influence microtubule stability by mechanisms that 
are both dependent and independent of its ability to bind to 
tubulin.
Dendritic and synaptic localisation of tau
Under physiological conditions, tau is located mainly in 
axons [21] and in significantly lower amounts in dendrites, 
including dendritic spines [226, 255]. The physiological 
role of tau in dendrites is not well understood, however, a 
recent study has implicated tau in regulating synaptic plas-
ticity in hippocampal neurons in response to brain-derived 
neurotrophic factor [73]. Furthermore, tau translocation to 
the post-synaptic compartment is dependent on neuronal 
activity [136]. Importantly, a novel role for tau in the mor-
phological and synaptic maturation of new-born hippocam-
pal granule neurons has recently been reported [382]. 
Tau is required for the proper formation of post-synaptic 
Nucleus
Mitochondrion
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Synapse
Fig. 4  Tau localisation in neurons. Schematic depicts the differing 
locations of neuronal tau, the majority of which is associated with the 
microtubule cytoskeleton in axons. Tau is also located in the soma-
todendritic compartment, including in mitochondria, the nucleus, 
plasma membrane, and synapses. Dendritic tau (indicated in red) is 
increased in the tauopathies
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densities, dendritic spines, and mossy fibre terminals and 
knocking out tau also reduces the sensitivity of new-born 
granule neurons to modulators of neurogenesis [382]. 
Notably, a recent study has shown that tau is involved in 
regulating the somatodendritic localisation and protein 
interactome of TIA1, an RNA-binding protein [488]. Tau 
is also involved in the formation, size and trafficking of 
stress granules, which has important implications both for 
the neuronal response to stress and for the pathogenesis of 
several neurodegenerative diseases [488]. Current evidence 
suggests that both the formation and trafficking of stress 
granules are modulated by tau which reduces the rate at 
which stress granules are trafficked in neurons [488]. How-
ever, since stress granules are transported on microtubules, 
the possibility cannot be excluded that defective trafficking 
could be caused by impaired tau-mediated stabilisation of 
microtubules in disease.
Association of tau with neuronal membranes
The N-terminal projection domain of tau is involved in reg-
ulating its interaction with the plasma membrane, in a pro-
cess mediated by annexin A2 [50, 154]. However, a recent 
structural analysis has identified specific regions located 
in the microtubule binding domain of tau that bind to lipid 
bilayers, indicating that multiple domains of tau might 
associate with membranes [156]. Tau has also been shown 
to be recruited to membranes by Fyn kinase, localised in 
lipid rafts [256]. The functional relevance of the association 
of tau with membranes is not well established but a role in 
neurite development, presumably by bridging the growing 
microtubules to the membrane cortex in the growth cone, 
has been suggested [154]. This view is supported by the 
observation that expression of a tau mutant capable of bind-
ing to Fyn, but lacking the microtubule binding domain, 
reduced both the number and the length of the processes 
elaborated by oligodendroglia [256]. Interactions between 
tau and membranes are also required for targeting tau to 
the cell surface to enable tau to participate in intracellular 
signalling pathways [397]. At the cell surface, tau can inter-
act with proteins involved in synaptic signalling, such as 
GluR2/3 subunits of the AMPA receptor [254].
Importantly, the association of tau with the plasma 
membrane is regulated by tau phosphorylation state [399, 
483]. Plasma membrane-associated tau is present in a rela-
tively dephosphorylated state in SH-SY5Y neuroblastoma 
cells, PC12 cells exogenously expressing tau, and cortical 
neurons [122, 399]. Furthermore, phosphorylation of tau, 
either directly or using pseudo-phosphorylated tau mutants 
in cultured cells, abolishes its interaction with cell mem-
branes [316, 399]. Such effects may be caused either by 
conformational changes effected by tau phosphorylation, or 
by altered interactions with other membrane-binding pro-
teins, such as Fyn tyrosine kinase [229, 411].
Interestingly, both in vivo and in vitro evidence has 
shown that tau-membrane interactions appear to correlate 
with tau aggregation [237]. One possible explanation for 
this finding is that direct binding of the microtubule bind-
ing domain of tau to the lipid surface of the membrane 
appears to alter tau secondary structure, which facilitates its 
aggregation [156]. Displacement of tau from microtubules, 
caused by increased tau phosphorylation or increased asso-
ciation of tau with phosphatidylserine in neuronal mem-
branes, could result in increased tau aggregation [450]. 
However, direct evidence obtained from cell or animal 
models of tauopathy is still needed to confirm this hypoth-
esis, and to establish the precise role of membrane-associ-
ated tau in neurons.
Nuclear tau
Nuclear tau has been reported in a wide variety of cell and 
animal systems, including in control and AD brain, human 
and rat neuroblastoma cells, and human non-neuronal cell 
lines [54]. To date, the transcript encoding nuclear tau has 
not been conclusively identified. There is evidence that 
the majority of nuclear tau may have comprised a specific 
isoform, possibly encoded by a transcript distinct from 
the 6 kb species, which encodes the six tau isoforms in 
the human CNS [509]. In support of this view, in murine 
brain the 1N4R tau isoform preferentially localises to the 
nucleus, with some also present in the soma and dendrites, 
but not in axons [295]. Other tau isoforms are also present, 
albeit in low amounts, within the nucleus [295]. Interest-
ingly, phosphorylation impacts on the behaviour of nuclear 
tau, especially its intranuclear localisation [54]. Reports 
indicate the existence of both phosphorylated and non-
phosphorylated tau in the nucleus [49, 177, 451], although 
it appears that the majority of nuclear tau present is in a 
non-phosphorylated form [309, 509].
In vitro studies have shown that tau can bind DNA and 
thereby increase its melting temperature [60]. Similar to 
its ability to bind microtubules, tau binding to DNA is 
dramatically reduced upon tau phosphorylation [403]. Tau 
binds to double stranded DNA in cooperation with his-
tones, and shows little or no sequence specificity, whereas 
binding of tau to single stranded DNA is sequence-spe-
cific [211, 265]. Binding to DNA is thought to be asso-
ciated with the ability of tau to protect against hydroxyl 
free radical-induced DNA breakage [60, 312]. In support 
of this notion, tau in primary cortical neurons displays 
several characteristics reminiscent of heat shock protein 
70 (HSP70) [467]. On exposure to heat stress, cytoplas-
mic tau translocates to the nucleus, where it protects the 
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integrity of DNA. In contrast, knocking out tau renders 
cortical neurons vulnerable to heat stress-induced DNA 
damage, and this vulnerability is mitigated by overex-
pression of tau [467]. Similarly, tau knockout neurons are 
more susceptible to hyperthermia-induced DNA and RNA 
breakage in comparison to their wild-type counterparts 
[495]. Furthermore, tau may be involved not only in DNA 
protection, but also in DNA repair mechanisms [495], 
although this remains controversial since others have 
reported that tau is not involved in DNA repair [421].
In addition to its function of protecting DNA, tau also 
showed potential as a modulator of gene expression. Tau 
binds to the AT-rich minor groove of DNA through its 
proline-rich and microtubule binding domains [403, 421].
The typical function of minor groove architectural bind-
ing proteins, such as high mobility group proteins, is to 
alter DNA conformation, causing it to unwind [34]. This 
altered DNA conformation enhances the assembly, sta-
bility and activity of multi-protein-DNA complexes, and 
indirectly either enhances or inhibits gene transcription 
[34]. Hence, it is possible that the interaction of tau with 
DNA could initiate the formation of a multi-protein com-
plex in a similar fashion to that of other minor groove 
binding proteins [177]. Indeed, the capacity of tau to 
change the conformation of DNA has been reported [467], 
resulting in modulation of gene expression. Genetic anal-
ysis of tau knockout mice suggests that tau could have an 
indirect effect on gene transcription, likely through com-
pensatory changes in gene expression. To date, the tran-
scription of at least 14 genes have been reported to be sig-
nificantly increased following tau depletion, all of which 
have been verified by microarray analysis in combination 
with quantitative real-time PCR [101, 379].
In addition to affecting DNA conformation and 
thereby gene transcription, tau colocalisation with his-
tones provides potential links between tau and organisa-
tion of heterochromatin, as has been observed in human 
skin fibroblasts and HeLa cells as well as in tau trans-
genic Drosophila and mice, and in AD [139, 456]. His-
tones and tau protein both bind to the minor groove of 
DNA and show similar effects in DNA retardation assays 
[60]. A recent study has revealed that tau binds to and 
localises either within or adjacent to neuronal heterochro-
matin in primary neuronal cultures from wild-type mice 
[322]. In tau knockout mice, the distribution pattern of 
the trimethylated forms of histone H3 and heterochroma-
tin protein 1α are disrupted. These findings support the 
view that tau may have a role as an epigenetic regulator 
of gene expression. In addition, tau is reported to contrib-
ute to chromosomal stability and to participate in the pro-
cessing and/or silencing of ribosomal RNA [309, 421].
In summary, it is becoming increasingly evident that 
nuclear tau plays roles in DNA protection, preserving 
its integrity, and possibly participating in DNA repair 
mechanisms. In addition, tau in the nucleus can regulate 
genomic function. However, tau is also reported to par-
ticipate in DNA damage responses, thereby dysregulating 
transcription [495]. Further research is needed to resolve 
these potentially discrepant findings.
Tau and neuronal activity
Pathological changes observed following depletion of 
murine tau have indicated the involvement of tau in the 
regulation of neuronal activity, neurogenesis, and long-term 
depression [255]. Tau knockout mice exhibit a selective defi-
cit in long-term depression, although not in long-term poten-
tiation (LTP), in the Cornu Ammonis 1 (CA1) region of the 
hippocampus, indicating a role for tau in synaptic plasticity 
[255]. Removal of tau leads to decreased migration of new-
born neurons from the subgranular zone of the hippocampal 
formation to the granular layer, suggesting a role for tau in 
neuronal migration [145]. Moreover, abolishing tau expres-
sion in adult mice results in a severely impaired hippocam-
pal neurogenesis [204], which may be related to the require-
ment for a dynamic microtubule cytoskeleton for efficient 
neurogenesis [146]. Importantly, recent investigation of neu-
rogenesis in tau knockout mice has elucidated new roles for 
tau in regulating the functional maturation and survival of 
new-born neurons, the selectivity of neuronal death follow-
ing stress, and neuronal responses to external stimuli [382].
However, it is notable that the phenotypic changes 
exhibited by different lines of tau-deficient mice have 
proved to be somewhat inconsistent due to several possi-
ble confounding factors (reviewed in [27]). First, changes 
induced by the absence of tau during neuronal develop-
ment may be variably compensated by increased expres-
sion of other microtubule-associated proteins, including 
MAP1A. Second, one tau knockout mouse line expresses 
part of tau exon 1, which could interact with tau bind-
ing proteins and/or membrane components. Third, some 
motor abnormalities observed in mice lacking tau appear 
to be age-related, and possibly associated with effects 
on the peripheral nervous system in some lines. Finally, 
phenotypic variation of different mouse lines can be 
strongly influenced by the specific mouse background 
used. Therefore, although tau-deficient mice are valuable 
models for assigning novel functions of tau, such findings 
need to be validated in multiple lines of mice.
Tauopathies
The heterogeneous group of dementias and move-
ment disorders that comprise the neurodegenerative 
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tauopathies are characterised neuropathologically by 
prominent intracellular accumulations of abnormal tau 
filaments that form neurofibrillary tangles, as well as 
other tau inclusions, in neurons and glia. Importantly, 
the discovery of multiple tau gene mutations in people 
with frontotemporal dementia exhibiting neuropathologi-
cal evidence of FTLD-tau has shown that certain MAPT 
mutations result in abnormalities in tau protein that cause 
neurodegenerative disease [158]. These seminal findings 
paved the way for further investigation of the role of tau 
in cognitive dysfunction and neurodegeneration. How-
ever, tau neuropathology rarely exists in isolation, and 
hence, most tauopathies exhibit pathological abnormali-
ties associated with the deposition of at least one other 
amyloidogenic protein, such as α-synuclein or huntingtin. 
This provokes the hypothesis that tau may have impor-
tant pathological roles in these disorders with multiple 
pathologies (see Fig. 5) [194, 233]. This heterogeneity 
gives rise to a spectrum of tauopathy diseases with over-
lapping but distinct pathologies. The nature of the asso-
ciated aggregated protein defines the neuropathological 
classification of the disease and may impact on the clini-
cal symptoms that characterise each group of disorders, 
as summarised below.
Tau in neurofibrillary tangles and amyloid pathology
Neuropathological Braak staging of AD brain characterises 
six progressive stages of disease propagation, which relate 
to the increasing severity of neurofibrillary tangle and amy-
loid plaque deposition in different brain regions [47]. The 
spread of AD pathology follows a consistent track through 
the brain, with neurofibrillary forms of tau appearing 
sequentially in the transentorhinal/peripheral cortex (Braak 
stage I), the CA1 region of the hippocampus (Braak stage 
II), limbic structures (Braak stage III), amygdala, thalamus 
and claustrum (Braak Stage IV), isocortical areas (Braak 
stage V), and finally, primary sensory, motor and visual 
regions (Braak stage VI) [46]. Based on the typical tempo-
ral-spatial progression of tau pathology in AD brain dem-
onstrated by classical Braak staging, it has been proposed 
that affected brain regions are likely to be anatomically 
connected.
Structural biology studies have revealed that the domi-
nant components of tangles in AD are paired helical and 
straight filaments, both types of filament being composed 
predominantly of abnormally phosphorylated tau protein 
[51, 261]. The actual molecular weight range of the six 
human CNS tau isoforms is 37–46 kDa (Fig. 1). However, 
on SDS-PAGE, tau in tangles extracted from AD brain 
resolves into three major bands with apparent molecu-
lar weights of 68, 64, and 60 kDa, with a minor band of 
approximately 72 kDa [176]. When dephosphorylated, tau 
from AD brain shows a similar band pattern to that of both 
dephosphorylated control adult human brain and recombi-
nant human tau, with apparent molecular weights ranging 
from 48 to 67 kDa [190]. The reason for this discrepancy 
between the actual and apparent molecular weights of tau 
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Fig. 5  Tauopathies. Diagram illustrating the wide range of neuro-
pathological conditions in which tau pathology is a significant fea-
ture. The central panel illustrates disorders in which tau pathology 
is the primary feature. The overlapping panels summarise condi-
tions in which tau inclusions are accompanied by deposits of other 
disease-associated proteins [19, 358, 445, 469]. 1Chronic traumatic 
encephalopathy includes traumatic brain injury and dementia pugilis-
tica; 2ARTAG, aging-related tau astrogliopathy includes globular glial 
tauopathy; 3PART, primary age-related tauopathy includes tangle-pre-
dominant dementia and clinically asymptomatic cases; FTLD, fronto-
temporal lobar degeneration
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extracted from human brain is due to a combination of 
post-translational modification and variable SDS binding. 
Tangles from AD brain contain both 3R and 4R tau iso-
forms in a one-to-one ratio, similar to the isoform composi-
tion of tau in control adult human brain [163]. However, in 
other tauopathies, the form of tau deposited is characterised 
by the over-representation of either 4R or 3R tau isoforms. 
For example, PSP and CBD exhibit predominantly 4R 
tau, whereas insoluble tau in PiD is mainly 3R tau, and in 
FTLD-tau the isoform predominance depends on the spe-
cific disease-causing tau mutation [17, 105].
Together with tau deposition, the accumulation of Aβ 
as amyloid plaques in the extracellular space and around 
blood vessels is used to for the neuropathological diagnosis 
of AD at post-mortem [519]. In contrast to tau, Aβ deposi-
tion does not correlate with cognitive decline and plaque 
pathology exhibits a pattern of spread that differs from that 
of tau in AD brain [238]. A direct relationship between 
Aβ-mediated toxicity and tau pathology has repeatedly 
been proposed [38, 307], although understanding of the 
mechanisms that link Aβ and tau deposition is incomplete. 
However, it is clear from genome wide association studies, 
that some genetic risk loci for AD, such as apolipoprotein E 
(APOE ε2, ε3, or ε4) influence both amyloid and tau [108]. 
One hypothesis for the pathogenesis of AD proposes that 
the development of neurodegeneration in AD depends on 
Aβ working in concert with tau. Thus, elevated Aβ in trans-
genic mice overexpressing APP induces tau phosphoryla-
tion and intracerebral injection of Aβ into tau transgenic 
mice increases tangle pathology [148, 287]. Furthermore, 
immunising transgenic 3xTg-AD mice, which express 
mutant forms of tau, APP and presenilin 1, and develop 
both tangle and amyloid pathologies, with antibodies rec-
ognising Aβ reduces the amount of phosphorylated tau 
[376].
However, several studies have shown that cognitive 
decline is not the inevitable result of harbouring a consider-
able load of amyloid and tau pathology in the brain [257, 
387, 438]. Aggregates gradual in AD correlates well with 
the number of tangles present; the demise of neurons far 
exceeds the degree of tangle pathology [147]. Furthermore, 
loss of synapses, potentially mediated by an as yet uniden-
tified factor or mechanism, rather than the burden of AD 
pathology, best correlates with cognitive decline [325].
Tau and α‑synuclein pathology
Parkinson’s disease is a neurodegenerative disease affect-
ing dopaminergic neurons. The principal pathological hall-
mark is the presence of Lewy bodies and Lewy neurites in 
the subcortical regions of the brain, which are composed 
of aggregated α-synuclein [464]. Hence, PD together with 
other α-synuclein related neurodegenerative disorders 
including Parkinson’s disease dementia, dementia with 
Lewy bodies, and multiple system atrophy, are collectively 
termed synucleinopathies [220, 463].
Notably, mutations in the MAPT gene cause variable 
extents of parkinsonism in affected people [215, 225]. 
These findings are supported by recent genome wide asso-
ciation studies, which have identified at least 24 genetic 
loci, of which the common genetic variants are associated 
with increased PD susceptibility [362]. Among these loci, 
the region encompassing the MAPT gene is one of the most 
significant hits, not only in rare familial cases but also in 
sporadic PD [270, 455]. It has been proposed that the H1 
haplotype, one of two common genetic variations at the 
MAPT locus, may be related to the occurrence of “pure” 
tauopathy and may be linked to elevated amounts of tau 
in plasma [72, 393] and synucleinopathies [170, 492], 
whereas the alternate H2 haplotype correlates with reduced 
expression of tau protein and thus may have a protective 
effect [501]. Importantly, tau could also serve as a pri-
mary driver of parkinson-related neurodegeneration, inde-
pendently of α-synuclein. Such a scenario exists in post-
encephalitic parkinsonism, a 3R/4R tauopathy that may be 
attributed to post-viral encephalitis, in which α-synuclein 
pathology is absent [501], in PSP, and in parkinsonism due 
to specific MAPT mutations. Together, these findings raise 
the possibility that tau can function both as a risk factor and 
as a mediator of parkinsonism.
The co-occurrence of aggregated tau and α-synuclein in 
tauopathies and synucleinopathies has led to investigations 
of the interplay between tau and α-synuclein [222, 423]. 
Notably, Lewy bodies have been detected in more than half 
of the AD brains that come to autopsy and up to half of 
PD brains have sufficient tau and amyloid pathology for a 
neuropathological diagnosis of AD [222, 353]. The pres-
ence of neurofibrillary tangles containing tau in sporadic 
PD, has also been described [235, 439] and both tau and 
α-synuclein are enriched in synaptic fractions of brains 
affected by either tauopathy or synucleinopathy [357]. 
Additionally, pronounced tau pathology, including co-
aggregation of tau and α-synuclein has been noted in famil-
ial Parkinson’s disease dementia [150, 401, 526]. Tau and 
α-synuclein colocalise in the same neuronal compartments, 
particularly in axons [124]. Moreover, tau fibrils are incor-
porated into Lewy bodies, colocalising with α-synuclein 
fibrils within individual aggregates [20, 223]. Further stud-
ies using mass spectrometry have also confirmed that tau 
is a component of Lewy bodies [232, 285] and increased 
phosphorylated tau has been shown to predict the rate of 
cognitive decline in PD [294].
In vitro studies have shown that co-incubation of tau and 
α-synuclein accelerates the fibrillisation of both proteins 
[159]. Tau expression also enhances the toxicity and secre-
tion of α-synuclein and promotes the formation of smaller 
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α-synuclein inclusions in human neuroglioma (H4) cells 
and primary neuronal cultures [26]. In turn, several stud-
ies have demonstrated that α-synuclein can promote tau 
phosphorylation. Nübling and colleagues showed that tau 
and α-synuclein can form detergent-resistant co-oligom-
ers, and formation of these aggregates is enhanced by tau 
phosphorylation [324, 374]. An in vitro study showed that 
tau phosphorylation is facilitated by α-synuclein via PKA 
[233]. Moreover, α-synuclein enhanced GSK3β-mediated 
tau phosphorylation by formation of a tripartite GSK3β/α-
synuclein/tau complex, resulting in the phosphorylation of 
tau at a number of residues [76, 247, 516]. Activation of 
MAPKs has also been reported in α-synuclein overexpress-
ing transgenic mice, correlating with the presence of phos-
phorylated tau [138, 375]. Moreover, a recent study has 
shown that, the transcriptional regulator, tripartite motif-
containing 28 (TRIM28), increases the amount of both tau 
and α-synuclein present in the nucleus, thereby increasing 
the toxicity of both proteins [423]. These findings suggest 
that in addition to the potential synergistic relationship 
between tau and α-synuclein they might also drive disease 
progression through shared mechanisms [423].
Together, these findings suggest that tau and α-synuclein 
interact to trigger formation of neuropathological lesions in 
the tauopathies and synucleinopathies. Events that increase 
the interaction of tau with α-synuclein could also modu-
late the activity of protein kinases and other tau modifying 
enzymes; thereby further influencing tau pathology and 
disease progression [353, 516].
Tau in Huntington’s disease
Recent evidence has shown that tau is also involved in the 
neuropathology of Huntington’s disease, an autosomal-
dominant movement disorder, in which cognitive decline 
is also a significant clinical feature [499]. HD is charac-
terised biochemically by the presence of abnormal expan-
sions of long polyglutamine tracts in huntingtin protein 
[269]. Increased amounts of total tau and phosphoryl-
ated tau, including rod-like deposits comprising mainly 
4R tau, are evident in the brains of people with HD [128, 
500]. A role has been proposed for huntingtin in the aber-
rant splicing of tau and the related microtubule-associated 
protein MAP2. The splicing factor SRSF6 accumulates in 
the striatum in HD and colocalises with nuclear inclusions 
bodies and other aggregates containing huntingtin [129]. 
Notably, SRSF6 is involved in the splicing of tau exon 10, 
which could provide an explanation for the deposition of 
4R tau in inclusions in HD [128, 500]. Further evidence 
for the involvement of tau in HD comes from studies of 
animal models, including the R6/2 mouse, which overex-
presses huntingtin exon 1 with an expanded polyglutamine 
repeat [64, 500]. R6/2 mice exhibit motor dysfunction and 
impaired learning and memory and intraneuronal inclu-
sions of mutant huntingtin [99, 292]. Notably, increased 
tau phosphorylation is evident in the brains of R6/2 mice in 
parallel with reduced amounts of protein phosphatases [39, 
174]. Increased tau phosphorylation has also been shown 
in HD, along with elevated GSK3 activity [268]. Taken 
together, these reports suggest a significant role for tau in 
the pathogenesis of HD.
Tau‑mediated neurodegeneration
Knowledge of the molecular mechanisms that under-
lie disease pathogenesis in the tauopathies is the subject 
of intense research. The following section focuses on the 
wide range of tau-related pathological events that occur at 
the molecular and cellular level during disease progression 
in the tauopathies. Alterations to the properties of tau that 
result from tau mis-splicing, aggregation, and post-transla-
tional modification, convert physiological forms of tau into 
pathological tau species that can cause tau to mislocalise in 
neurons. In addition, the detrimental effects of pathological 
tau may be amplified by dysfunction of multiple molecu-
lar pathways, including those involved in synaptic function, 
axonal transport, and protein quality control. Such patho-
logical events could also act synergistically and elicit not 
only local cytotoxic effects but also fuel the intercellular 
spreading of tau pathology, and involve both neurons and 
glia.
Tau gene dysfunction: mutations and splicing 
imbalance
P301L was the first mutation identified in the MAPT gene 
which resulted in tau dysfunction and neuronal death in 
FTLD-tau [213, 400]. Since then, a large number of muta-
tions in MAPT have been reported to cause FTLD-tau, but 
notably, to date no mutations in MAPT have been associ-
ated with the development of AD [158]. Mutations in 
MAPT give rise to several different clinical phenotypes, 
the majority of which are frontotemporal dementia, but 
which also include Parkinson’s disease dementia, PSP, PD, 
AD, LBD, CBD, PiD, AGD, and FTD/amyotrophic lateral 
sclerosis (ALS). Certain MAPT mutations affect the ratio 
of 3R and 4R tau isoforms and increase tau phosphoryla-
tion [6]. Since 4R tau isoforms have a higher propensity 
to bind to microtubules, the presence of mutations can 
also have a significant influence on tau-microtubule bind-
ing [112, 311]. The influence of specific disease-associated 
mutations in tau on its functions beyond microtubule bind-
ing has yet to be well established. However, it is clear that 
MAPT mutations are detrimental to neurons and likely to 
impact on the conformation of tau, with resultant effects on 
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its post-translational modification, interaction with other 
proteins, and a variety of intracellular processes.
Tau aggregation
One of the most prevalent ideas about how tau contributes 
to the pathogenesis of tauopathies is that tau undergoes 
misfolding and oligomerisation into insoluble tau deposits. 
These tau aggregates gradually overburden neurons, affect 
fundamental cell functions and ultimately cause neuronal 
death [514]. Indeed, the appearance of tau deposits has 
been regarded as a typical pathological signature in many 
tauopathies, especially AD, and is used as an indicator of 
disease stage [47].
The structural basis of the aggregation propensity of 
tau lies in the two hexapeptide motifs located in the sec-
ond and third microtubule binding repeats that display high 
β-sheet propensity and are further characterised as drivers 
of the abnormal self-assembly of tau [354, 355]. The hexa-
peptide motifs comprise tau residues 306–311 (PHF6, Val-
Gln-Ile-Val-Lys-Tyr, VQIVKY) and 317–335 (PHF6*, Val-
Gln-Ile-Ile-Lys-Tyr VQIINK) [380]. These regions of tau 
self-assemble in the absence of additional chemical stimuli 
[433, 498]. In vitro studies have demonstrated that PHF6 
and PHF6* can form fibrillar aggregates in the presence of 
ammonium acetate [497]. PHF6 is located at the beginning 
of the third microtubule binding repeat and is present in all 
tau isoforms. In contrast, PHF6* is located at the beginning 
of the second microtubule binding repeat. Tau dimerisa-
tion can occur through interactions between two PHF6, two 
PHF6*, or between one PHF6 and one PHF6* motif [391]. 
Further recruitment of tau monomers and dimers could lead 
to the formation of a nucleation centre and once a critical 
cluster size is reached, tau oligomerisation can proceed in a 
dose and time-dependent manner [29]. Finally, tau oligom-
ers elongate into protomers, which adopt a parallel, in reg-
ister, cross β-sheet structure, typical of amyloid aggregates 
[332]. Ultimately, these tau filaments become the building 
blocks of neurofibrillary pathology in the tauopathies.
Although PHF6 and PHF6* motifs are prone to self-
assembly, native tau is relatively resistant to aggregation. 
Hence, factors which enhance the assembly propensity of 
tau, or neutralise its charge, facilitate tau aggregation. Due 
to the presence of PHF6*, which is encoded by exon 10, 
4R tau isoforms are more prone to aggregation than 3R tau 
isoforms. Mutations within the tau hexapeptide motif that 
enhance β-sheet propensity, such as the P301L tau muta-
tion found in FTLD-tau, promote tau aggregation [288]. 
Conversely, introduction into these hexapeptide motifs of 
amino acid substitutions, such as proline residues, that dis-
rupt β-sheet structure, render tau incompetent for assem-
bly [55]. Notably, in addition to the increased aggregation 
propensity of exon 10, exons 2 and 3 also influence the 
kinetics of tau aggregation. The N-terminal insert encoded 
by exon 2 promotes tau aggregation, whereas expression 
of exon 3 exerts an inhibitory effect on tau aggregation in 
a process which is modulated by expression of exon 10 
[540]. However, whether such effects result from changes 
in the overall charge of tau due to inclusion of the N-ter-
minal inserts is unclear. Deletion of the positively charged 
Lys(K)280 residue, which is involved in localised electro-
static interactions, hinders tau self-assembly [497]. Phos-
phorylation of tau on serines, threonines and tyrosines, 
causes tau to become more negatively charged and tau acet-
ylation neutralises positively charged lysine residues. Both 
of these post-translational modifications effectively reduce 
the overall positive charge on tau and can impact on tau 
folding. Furthermore, anionic condensing agents are well-
documented as aggregation inducers. For example, heparin 
can bind to tau at multiple sites within the second and third 
microtubule binding repeats, as well as the flanking region 
and the N terminus, thereby stabilising assembly competent 
intermediates [267, 453]. Fatty acids, tRNA, and polyglu-
tamic acid can also promote tau aggregation, although the 
regions of tau that bind these agents only partially overlap 
with those of heparin [517].
Neurofibrillary tangles have long been considered toxic 
to neurons. However, recent findings have challenged this 
view [92]. An in vivo model in which formaldehyde was 
used to treat primary hippocampal neurons showed that 
tau aggregates could induce apoptosis [363]. Toxicity 
was also observed in N2a mouse neuroblastoma cells in 
which expression of a fragment of mutant K18ΔK280 tau 
 (Tau258–360, lacking K280) either alone, or together with 
full-length mutant tau (ΔK280) caused cytotoxicity [513]. 
The N2a cells expressing K18ΔK280 tau were positive 
for thioflavin S staining, implying that tau aggregation is 
closely associated with cytotoxicity. In contrast, findings 
from transgenic mice inducibly expressing P301L tau, 
demonstrated an improvement in memory, and neuronal 
loss was halted, when the mutant tau gene was switched 
off, despite tangle burden not being reduced [435]. Further 
studies showed that, tangle-bearing neurons appear to sur-
vive in inducible P301L tau-expressing mice, despite the 
apparent membrane disruption in affected neurons [104]. 
Whether tangles are toxic per se is still unknown, how-
ever, it is likely that tau species that are generated during 
the formation of tangles are damaging to cells. The precise 
nature of the tau species that result in neurotoxicity remain 
to be determined, but there is accumulating evidence that 
soluble oligomeric forms of tau, that may be generated dur-
ing tangle formation, are damaging to neurons and to syn-
aptic function [272, 465]. However, as discussed above, 
tau aggregation is affected by factors including mutation, 
isoform composition, and post-translational modifica-
tion. Consequently, a variety of tau species with differing 
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morphology, solubility, and disease-relevant properties 
can be generated. These differing forms of tau may form 
the molecular basis of distinct tau “strains” and might con-
tribute to the wide degree of clinical and neuropathological 
heterogeneity observed in the tauopathies [432].
Tau truncation
Proteolytic cleavage of disease-modifying proteins is found 
in a wide variety of human neurodegenerative diseases, 
including AD [151, 208, 373, 518], PiD [183, 343], CBD 
and PSP [16], transactive response DNA-binding protein 
43 (TDP-43)-related FTLD [214], and PD [12], as well 
as polyglutamine diseases, such as Huntington’s disease 
[149].
The discovery of a protease-resistant core of tau within 
the paired helical filaments that comprise neurofibril-
lary tangles in AD brain was initially shown using a spe-
cific antibody that recognised a neoepitope generated by 
tau cleavage [165, 518]. These findings revealed that the 
core consists of tau fragments of 12 and 9.5 kDa, and the 
same antibody was shown to recognise tau protein that was 
C-terminally truncated at Glu391 (Table 2) [373]. The pro-
tease resistance of this 12 kDa form of tau led to the sug-
gestion that truncation may be the mechanism that modifies 
tau such that it becomes prone to misfolding, adopting an 
abnormal conformation and self-assembling into filaments 
more readily than does full-length tau [372]. This view is 
supported in a study using DC11, a truncation-dependent 
conformational antibody, which recognises abnormal tau in 
AD brain but not tau in control brain [489]. Recombinant 
tau proteins truncated either at the N terminus or at both the 
N and C termini, are also recognised by DC11, indicating 
that both N- and C-terminally truncated tau species are pre-
sent in tauopathy brain and can adopt pathological confor-
mations [489]. Similarly, in vitro studies of tau aggregation 
have indicated that truncations occurring at Glu391 and 
Asp421, produce tau proteins that are more prone to aggre-
gation than full-length tau [3, 33]. Together these findings 
provided the first in situ evidence that tau truncation might 
be a pathological mechanism in tauopathies.
Tau truncated at Asp421 colocalises with tangles in AD 
brain as well as in a number of transgenic mouse models 
of AD, indicating that the generation of this tau fragment 
may be an early event in tangle formation [30, 151, 208]. 
Similarly, expression of  Tau151–391, including either three 
 (Tau151–3913R) or four  (Tau151–3914R) microtubule binding 
repeats, in the brains of transgenic rats induces neurofibril-
lary pathology that resembles human tauopathy [132, 262, 
542]. Rats expressing either  Tau151–3913R or  Tau151–3914R 
exhibit pathological features including age-dependent 
increases in tau phosphorylation at multiple epitopes, and 
Gallyas-positive intracellular and extracellular tangles, 
which were positive for Congo red birefringence and thio-
flavin S [542]. Notably, extraction of sarkosyl-insoluble tau 
from  Tau151–391 rat brain showed that these truncated forms 
of tau co-aggregate with endogenous rat tau [132]. These 
findings show that tau truncation facilitates misfolding of 
intact tau, which could be responsible for the generation of 
tangles in the brain in AD and related tauopathies.
Several other tau fragments have been described in a 
range of different tauopathies. An N-terminal neurotoxic 
tau fragment  (Tau26–230) termed NH2-tau, has been detected 
in human SH-SY5Y cells undergoing apoptosis and also 
in the hippocampus of aged AD11 transgenic mice, which 
express antibodies to nerve growth factor and exhibit AD-
like pathology, including Aβ accumulation and hippocam-
pal-dependent memory deficits [89].  Tau26–230 is enriched 
in mitochondria isolated from AD synaptosomes [90], and 
this observation correlates with the altered function and 
quality control of mitochondria at synapses, as well as 
with synaptic dysfunction in AD [10]. Increased amounts 
of a 20 kDa C-terminally truncated tau fragment were pre-
sent in synaptosomes from AD brain, compared to control 
brain [459]. A 33 kDa N-terminally truncated form of tau 
(starting at residue Ser71 in 0N3R tau, equivalent to Ser128 
in 2N4R tau) was found in preparations of tangles puri-
fied from human AD brain [364]. A 17 kDa tau fragment 
 (Tau73–315) was identified in cerebellar granule neurons 
undergoing apoptosis [62]. Interestingly, a different 17 kDa 
tau fragment  (Tau45–230) was found in hippocampal neurons 
treated with Aβ [384] and also in post-mortem AD brain, 
and in a transgenic mouse expressing both human APP and 
tau [131, 414]. Overexpression of  Tau45–230 induced apop-
tosis both in CHO cells and in neurons, and hence  Tau45–230 
has been proposed to have inherent neurotoxic properties 
[384]. However, these findings are controversial since oth-
ers have reported this tau species to be smaller (11 kDa), 
to comprise residues  Tau125–230, and to lack neurotoxicity 
[152]. Interestingly,  Tau45–230 accumulates in lumbar and 
cervical spinal cord, as well as in upper motor neurons 
located in the precentral gyrus in ALS [493], suggesting 
that tau fragmentation may also have an important role in 
degeneration of motor neurons in ALS.
A 35 kDa C-terminal tau fragment  (Tau187–441) lacking 
the N terminus of tau has been identified in neurodegen-
erative disorders characterised by overexpression of 4R tau 
isoforms, particularly in PSP [520]. Tau35 contains all four 
microtubule binding repeats and is highly phosphorylated in 
brains affected by tauopathy [520]. Minimal expression of 
Tau35 in transgenic mice is sufficient to cause several key 
features of human tauopathy, including aggregates formed 
of abnormally phosphorylated tau, progressive cognitive 
and motor deficits, and loss of synaptic components [42]. 
Similarly, another C-terminal tau fragment  (Tau243–441), 
termed Tau-CTF24, was detected in Tg601 transgenic mice 
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or alternatively such cleavage could induce and drive aggre-
gation of tau and any associated disease-modifying proteins, 
leading to a loss of tau function. Supporting the latter sce-
nario is the fact that truncated protein fragments can form 
the initial seeds required for aggregation and appear to be 
upstream in the proteopathic cascade that occurs in neurode-
generative disease [102, 132, 173, 214, 286, 542].
Table 2  Tau fragments identified in human brain that may be involved in human tauopathies
Tau fragment Amino acid residues Mr (kDa) Comments References
C-terminally 
cleaved tau
M1- 40–53 Present in synaptosomes from AD brain
C terminus not identified
[459]
Delta tau H14/A15-D421 Associates with tangles in AD brain
Identified in the brains of aged wild-type and transgenic 3xTg-AD 
and htau mice, which develop tangles, amyloid plaques and synaptic 
dysfunction. Induces tau filament formation and inversely corre-
lates with cognitive function. Induced by Aβ in neurons and leads 
to apoptosis. Tau is cleaved at D13 by caspase-6 and at D421 by 
caspase-3
[30, 125, 151, 
182, 208, 330, 
369, 412]
NH2-tau Q26-R230 Enriched in synaptosomal mitochondria in AD brain
Induced by apoptosis in SHSY-5Y neuroblastoma cells. Present in 
hippocampus in AD11 transgenic mice which have chronic NGF 
deprivation during adulthood and display AD-like molecular and 
behavioural phenotypes
[7–10, 24, 89, 
90, 404]
E45-R230 17 Detected in AD, ALS, and control brain
Generated in neurons by exposure to Aβ or by thapsigargin-mediated 
inhibition of autophagy. Induces neurodegeneration when expressed 
in mice. Not toxic when expressed in N2a or CHO cells, or neurons
Generated by calpain-1 cleavage
See related fragment A125-R230 below
[152, 271, 384, 
414, 493]
S129-(S71 in 0N3R tau) 33 Isolated from tangles in AD brain
Decreased ability to bind to tubulin. C terminus not identified
[364]
Q124-L441 43 Present in human brain
Increased acetylation and detyrosination of tubulin when expressed in 
N1E-115 neuroblastoma cells
[109]
A125-R230 17 Present in AD and control brain
Not toxic when expressed in N2a or CHO cells, or neurons. Generated 
by calpain-2 cleavage
See related fragment E45-R230 above
[152]
I151-A391 29 Present in the neurofibrillary tangle core in AD brain
Expression of either 3R  tau151–391 (lacking 275–305) or 4R  tau151–391 
in transgenic rats induces tangle formation. Muscle weakness devel-
ops only in 4R  tau151–391 rats
[132, 331, 373, 
542]
Tau35 E187-L441 33–37 Present in AGD, PSP, and CBD, but not control brain
Includes four microtubule binding repeats. Expression of Tau35 mice 
in transgenic mice induces tau pathology, cognitive and motor 
dysfunction
[16, 42, 216, 
520]
Tau-CTF24 L243-L441 24 20–28 kDa C-terminal tau species detected in AD, CBD, PSP, and 
FTLD-tau, but not control brain
Includes four microtubule binding repeats. Present in Tg601 mice 
which exhibit increased tau phosphorylation and synapse loss
[327]
Tau fragments that have been detected in human brain that is potentially associated with the development of tauopathy. The tau cleavage prod-
ucts are listed in order of their most N-terminal amino acid (single letter code). 3xTg-AD mice are transgenic for mutant forms of tau, amyloid 
precursor protein, and presenilin 1 [377]; AD11 mice are transgenic for NGF antibodies [63]; Tau35 mice are transgenic for the wild-type human 
tau fragment E187-L441 [42]; Tg601 mice are transgenic for wild-type 2N4R tau [240]
3R tau isoforms containing three microtubule binding repeats, 4R tau isoforms containing four microtubule binding repeats, Aβ amyloid-β pep-
tide, AD Alzheimer’s disease, AGD argyrophilic brain disease, ALS amyotrophic lateral sclerosis, CBD corticobasal degeneration, CHO Chinese 
hamster ovary, FTLD frontotemporal lobar degeneration, PSP progressive supranuclear palsy
overexpressing wild-type human 2N4R tau [327]. Tg601 
mice exhibit synapse loss in the nucleus accumbens and 
axonopathy in the ventral medial prefrontal cortex, as well 
as increased tau phosphorylation at the PHF1 epitope (phos-
phorylated Ser296/Ser404) in the striatum [240].
Tau cleavage could either generate fragments with a toxic 
gain of function, thereby switching on a cell death cascade, 
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Along with the increasing number of tau fragments 
identified in cell and animal models of disease, increasing 
numbers of proteases that may be candidates for tau trun-
cation have been identified. Proteases targeting tau include 
caspases, calpains, thrombin, cathepsins, asparagine endo-
peptidase (AEP), puromycin-sensitive aminopeptidase 
(PSA), human high temperature requirement serine pro-
tease A1 (HTRA1), and proteasomal proteases, which are 
described in more detail below [192, 508, 537].
Caspases
Caspases recognise at least four contiguous amino acids 
on their substrates, with an absolute requirement for an 
aspartate residue in the P1 position before the scissile bond 
[81]. Asp421 in tau is targeted by caspases-1, -3, -6, -7 and 
-8, generating tau fragments that are approximately 5 kDa 
smaller than full-length tau due to the removal of C ter-
minus [151, 412]. In vitro, caspase-6 cleaves tau at Asp13 
even more efficiently than the cleavage at Asp421, and 
these cleavage sites have both been validated by N-terminal 
protein sequencing or/and mass spectrometry [151, 208, 
412]. Although activated caspase-6 has been found to colo-
calise with tau aggregates in AD brain, direct evidence of 
tau truncation at Asp13 in AD remains elusive [185]. Trun-
cation of tau at Asp402, a putative caspase-6 cleavage site, 
has also been identified in transgenic animals, and Asp25 
cleavage of tau, possibly due to the action of caspase-3 has 
also been detected in AD brain [185, 418]. However, to 
date, these sites have not been shown to be cleaved by any 
known caspases, at least in vitro [151]. Thus, only tau trun-
cation at Asp421 by caspases has so far been validated both 
in vitro and in vivo and appears to be directly related to the 
development of tau pathology. Recently,  Tau26–230, which 
has been reported to be neurotoxic in primary neuronal cul-
tures, possible due to its effects on mitochondria, has also 
been found to be a product of caspase cleavage that is gen-
erated during apoptosis [10, 89, 90].
Further studies have identified a tau fragment cleaved 
at Asp421 by caspase-3 in COS and NTera-2 (NT2) cells 
transfected with human tau [125], in rodent primary cul-
tured neurons [153], and htau [13] transgenic mice [369]. 
The presence of these caspase-cleaved tau products in AD 
brain was identified using antibodies TauC3 and α-ΔTau, 
which are specific for caspase-cleaved tau (Table 2) [151, 
412]. TauC3 antibody also revealed consistent labelling of 
tangles and plaque-associated dystrophic neurites in the 
CA region of the hippocampus in human vascular dementia 
brain [100]. In addition, active caspase-3 colocalises with 
TauC3 labelling in plaques, blood vessels and pre-tangle 
neurons in AD brain [100]. Notably, cognitive decline and 
formation of tangles in aged wild-type mice also correlates 
with increases in caspase activity and caspase-3 truncated 
tau [330]. Similarly, in AD brain, caspase-6-cleaved tau 
fragments are associated with both pre-tangles and mature 
tangles, and these truncated forms of tau appear to correlate 
well with cognitive decline [151, 185, 208]. De Calignon 
and colleagues have shown that transient activation of exe-
cutioner caspases in neurons of Tg4510 transgenic mice 
which inducibly express human P301L tau, leads to tau 
cleavage at Asp421 [102]. The resultant tau fragments gen-
erated by caspases exhibits tangle-related conformational 
epitopes, and thioflavin S-positive tangles [102]. Moreover, 
expression of  Tau151–421 in hippocampal neurons leads to 
the induction of apoptosis, suggesting that caspase cleavage 
of tau at Asp421 might convert it into an apoptotic effector 
[125].  Tau151–421 also induces mitochondrial fragmentation 
and elevates oxidative stress in cells [66, 404]. Addition-
ally, caspase-2 is also reported to cleave tau at Asp314 gen-
erating a N-terminal fragment. This fragment exhibited low 
propensity of fibrillation, but is able to infiltrate spines and 
dislocate glutamate receptors, causing synaptic dysfunction 
[539].
Notably, pseudophosphorylation of Ser422 can abolish 
in vitro tau truncation by caspase-3 at Asp421 [181] and 
can also enhance tau aggregation and impair axonal trans-
port [476]. Together with the finding that phosphorylation 
of Ser422 in AD brain appears to precede truncation at 
Asp421 during neurofibrillary tangle maturation, this indi-
cates that tau phosphorylation on Ser422 could inhibit tau 
cleavage by caspase in vivo [181].
Calpains
Calpains are cytosolic calcium-activated cysteine proteases, 
which exist as two major forms, calpain-1 and calpain-2 
[166]. In addition to regulation by calcium, calpain activ-
ity is also negatively regulated by calpastatin, a calcium-
dependent heat-stable calpain inhibitor. Protein cleavage by 
calpains is related only weakly to amino acid sequence and 
is more closely associated with polypeptide conformation 
[96, 479].
Increased calpain activity and depletion of calpastatin 
are observed in AD brain in comparison to age-matched 
controls [407, 427]. Several studies have shown that tau can 
be degraded by calpains in vitro [236]. Aβ treatment of cul-
tured neurons leads to calpain activation and production of 
 Tau45–230, suggesting that this tau fragment is generated by 
the action of calpain [384]. Highly phosphorylated insolu-
ble tau in AD brain is less susceptible to calpain degrada-
tion than is soluble tau which has a lower phosphorylation 
state [293, 333], suggesting that phosphorylation may be 
linked to tau cleavage in vivo. However, calpain-mediated 
tau cleavage in AD brain may also be hampered by the con-
formation adopted by insoluble tau during its deposition in 
disease.
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Thrombin
Thrombin is an extracellular serine protease generated by 
proteolytic cleavage of its precursor, prothrombin [127]. 
Thrombin has also been reported to be present in tangles 
in AD brain [5, 18], implying that it may be related to tau 
aggregation. Prothrombin mRNA is expressed in several 
regions of the rat and human nervous system [113], and 
both prothrombin and thrombin proteins are expressed in 
neurons [18]. It has been proposed therefore that throm-
bin could proteolyse tau in the brain, which is supported 
by the finding that in brain lysates incubated with different 
protease inhibitors, specific inhibition of thrombin in brain 
homogenates reduces tau degradation [15]. In vitro, tau is 
cleaved by thrombin at multiple arginine and lysine sites 
including Arg155, Arg209, Arg230, Lys257 and Lys340. 
The initial cleavage occurs at Arg155, producing a tau frag-
ment of 37 kDa [513]. This truncated tau polypeptide is 
then subsequently cleaved at Arg230, yielding a 25 kDa tau 
fragment [378]. The resultant C-terminal tau fragment has 
a reduced capacity to promote microtubule assembly com-
pared with full-length tau [378].
Phosphorylation of tau appears to make it more resistant 
to thrombin cleavage similar to the situation with caspases 
and calpains. Thus, thrombin cleavage of tau at Arg209, 
Arg230, Lys257 and Lys340 is suppressed by GSK3-medi-
ated phosphorylation of tau at Thr212, Thr231 and Ser396/
Ser404 and dephosphorylation of insoluble aggregated tau 
from AD brain causes it to become more susceptible to 
thrombin degradation [15]. PKA phosphorylation of tau 
also induces resistance to thrombin cleavage [506], sup-
porting the view that phosphorylation may be a mechanism 
that dynamically modulates tau proteolysis.
Cathepsins
Several groups have shown in vitro that tau is cleaved by 
cathepsin D between amino acids 200 and 257, resulting 
in the generation of a 29 kDa tau species [31, 251]. Active 
cathepsin D and cathepsin B have been found in amyloid 
plaques in AD brain [65]. In human neuroblastoma cells 
inducibly expressing tau, disruption of lysosomes with 
chloroquine to releasing lysosomal proteases including 
cathepsins, results in inhibition of tau degradation and the 
appearance of tau aggregates [186]. In N2a cell expressing 
 tauRDΔK280, a tau fragment comprising the microtubule 
binding repeats but lacking Lys280, active cathepsin L gen-
erated amyloidogenic tau fragments, thereby indicating a 
role for cathepsin in tau aggregation [512]. In contrast with 
the degradation of tau by calpain, caspase-3 or thrombin, 
whereby tau phosphorylation suppresses proteolysis, tau 
degradation by cathepsin D appears to be accelerated by 
enhanced phosphorylation in vitro [251].
As cathepsins are primarily lysosomal proteases, an 
important question is how these enzymes could gain access 
to tau in neurons. One possibility is that inefficient translo-
cation of tau or tau fragments across the lysosomal mem-
brane could result in incomplete lysosomal cleavage of 
tau, generating small tau fragments [512]. In AD brain and 
under other conditions of cellular stress, cathepsin D and 
other proteases could contribute to tau proteolysis when the 
lysosomal system is disturbed [11, 42].
Asparagine endopeptidase
Another lysosomal cysteine proteinase, asparagine endo-
peptidase (AEP), has recently emerged as a tau protease. 
AEP degrades tau by cleaving it C-terminally at asparagine 
residues, abolishing the microtubule assembly function of 
tau and inducing its aggregation [537]. Notably, AEP is 
upregulated in human AD brain and in the brains of P301S 
tau transgenic mice. Knockdown of the AEP gene in P301S 
tau mice results in substantially reduced tau phosphoryla-
tion, rescue of synaptic function impairment and recov-
ery of cognitive deficits. Furthermore, introduction of the 
N255A/N368A tau mutant, which abolished AEP cleav-
age at these two sites, also attenuated the pathological and 
behavioural defects in the P301S tau mice. Together with 
its recognition of APP as a substrate of AEP, these findings 
have resulted in the suggestion that AEP could be a useful 
target for therapeutic intervention in the tauopathies [538].
Puromycin‑sensitive aminopeptidase
Puromycin-sensitive aminopeptidase (PSA) is found in 
neurons, but not in surrounding glial cells or in blood ves-
sels [478] and comprises over 90% of the aminopeptidase 
activity in the brain [328]. PSA can digest tau isolated from 
brain tissue in vitro and expression of PSA is inversely cor-
related with vulnerability to tau pathology [244, 443]. In 
Drosophila expressing human tau, PSA expression reduced 
the amount of tau and protected against tau-induced neuro-
degeneration, whereas flies expressing a PSA loss-of-func-
tion mutant exhibited exacerbated neurodegeneration [244]. 
Hence, PSA could modulate the amount of tau present in 
the brain. Interestingly, in FTLD-tau brain tissue, expres-
sion of PSA is elevated fivefold in the cerebellum com-
pared with the frontal cortex [244]. This finding, combined 
with the observation that the cerebellum is less affected 
than cerebral cortex in the tauopathies [77], reinforce the 
potential protective role of PSA against neurodegeneration.
Human high temperature requirement serine protease A1
Human high temperature requirement serine protease 
A1 (HTRA1) is a secreted ubiquitously expressed, 
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ATP-independent serine protease with intrinsic disag-
gregating activity [78]. Mutations in HTRA1 are associ-
ated with the development of age-related macular degen-
eration and small vessel disease, and recently HTRA1 has 
been shown to colocalise with tangles and plaques in AD 
brain [175, 193]. There is an inverse correlation between 
HTRA1 and plaque and tangle numbers in AD brain and 
in keeping with this total amount of tau and phosphoryl-
ated tau inversely correlate with HTRA1 in AD, but not 
in control brain [475]. HTRA1 can degrade both soluble 
and aggregated tau at multiple sites, producing a range of 
small tau fragments ranging from 9 to 22 residues in length 
[475]. Little is known regarding the consensus sequences 
required for HTRA1 cleavage, although cleavage after the 
hydrophobic amino acids Val, Leu, and Ile are preferred 
sites in tau. HTRA1 appears to preferentially target N- and 
C-terminal regions of aggregated tau, cleaving tau within 
the microtubule binding domain [395]. Due to its intrinsic 
ability to solubilise misfolded proteins, HTRA1 can both 
disaggregate and proteolyse tau. This ability has recently 
been demonstrated in HEK293T cells expressing P301L 
tau aggregates, in which HTRA1 was able to solubilise tau 
and to enhance its degradation [395]. Furthermore, when 
tau was exogenously expressed in PC12 cells colocalisation 
of HTRA1 and tau with microtubules was demonstrated, 
alongside increased HTRA1 mRNA and HTRA1 activ-
ity [475]. Thus, HTRA1 could target aggregated tau and 
potentially limit the spread of tau pathology in the tauopa-
thies by inducing its cleavage and clearance [395].
The ubiquitin‑proteasome system
The ubiquitin-proteasome system (UPS) regulates pro-
tein quality control in both the cytoplasm and the nucleus 
by eliminating damaged, misfolded, and mutant proteins 
[279]. Blocking the activity of the proteasome catalytic 
core inhibits tau degradation in SH-SY5Y cells expressing 
exogenous human tau [98]. Furthermore, in vitro studies 
have shown that the proteasome degrades unfolded recom-
binant tau in an ubiquitin-independent manner, generating 
stable tau intermediates of approximately 27 and 17 kDa 
[98, 510]. In AD brain, proteasome activity is decreased, 
which could contribute to the accumulation of protein 
aggregates, including tau filaments [250, 428].
Axonal transport impairment in the tauopathies
Besides regulating microtubule dynamics, tau regulates 
the axonal transport of proteins and organelles by influenc-
ing the motor proteins dynein and kinesin. Whilst dyneins 
transport cargoes towards the minus ends of microtubules, 
directing them to the cell body, the majority of kinesins 
transport cargoes towards the plus ends of microtubules 
in the direction of the axon terminus [106, 326]. Tau can 
dynamically regulate the function of the axonal transport 
machinery through multiple mechanisms [115, 120, 485].
Axonal and cell body accumulations of organelles and 
other proteins frequently occur in neurodegenerative dis-
ease, leading to the appearance of axonal swellings and 
spheroids [337]. Such pathologies suggest that defective 
functioning of axonal transport may contribute to disease. 
Axonal transport requires intact microtubules, functional 
motor proteins, correct cargo attachment to motors, and 
sufficient ATP, supplied by mitochondria. Thus, each of 
these four components of the axonal transport system can 
be a target of pathogenic proteins [106]. Indeed, axonal 
transport defects have been described as an early pathologi-
cal feature in a variety of animal models of AD and tauopa-
thies [28]. Neurons containing tangles exhibit severely 
impaired anterograde transport along axons as well as in 
basal dendrites and impaired retrograde transport in apical 
dendrites [106, 337].
Recent work supports the idea that tau affects axonal 
transport by both compromising the structure of microtu-
bules, and disrupting components of the axonal transport 
machinery. Abnormal modification of tau, such as increased 
phosphorylation, truncation and acetylation, impairs the 
interaction of tau with microtubules and the ability of tau 
to stabilise microtubules [351, 480]. Moreover, pathologi-
cal forms of tau have a reduced ability to promote microtu-
bule assembly and form an organised cytoskeletal network 
[161]. Furthermore, overexpression of mutant or wild-type 
tau in mice results in dendritic missorting of tau and desta-
bilisation of microtubules, an effect that can be rescued 
by microtubule-stabilising drugs [536]. Mislocalisation of 
tau to dendrites is a neuropathological feature of AD brain 
which occurs early during disease pathogenesis, possibly 
even pre-clinically, and prior to tau aggregation [45, 74]. 
Loss of tau function therefore leads to a loss of the micro-
tubule tracks required for efficient axonal transport. In 
addition, reduced tubulin acetylation has been observed in 
neurons containing tangles in AD brain [198], indicating 
that tubulin acetylation could also be involved in impairing 
axonal transport.
Tau also interferes with binding of the molecular motor 
proteins dynein and kinesin, to microtubules. Tau reduces 
the binding frequency as well as the mobility of these two 
proteins, slowing both anterograde and retrograde trans-
port [441]. Overexpression and mislocalisation of tau 
modulates kinesin-based transport by directly inhibiting the 
access of these motors to microtubule tracks [120]. More-
over, in vitro studies have revealed that tau inhibits kine-
sin-mediated transport, not only by reducing the distance 
travelled by individual kinesins but also by reducing their 
velocity [115, 120, 466]. Tau reduces the number of motors 
that are engaged with cargoes and thereby interferes with 
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axonal transport of cargoes [491]. Protein levels of both the 
kinesin motor-mediated axonal transport machinery and of 
the dynein-mediated retrograde transport machinery are 
reduced in AD [346]. Such reductions, especially of kine-
sin light chain and dynein intermediate chain compromise 
the capacity of these motor proteins. Tau sequesters the 
available kinesin, and thereby limits axonal transport of 
other cargoes [258, 485] and regulates the release of cargo 
vesicles from kinesin chains by activating PP1 and GSK3β 
[242]. Thus, increased activation of GSK3β contributes to 
transport deficits by aberrant phosphorylation of light chain 
of kinesin, resulting in premature release of kinesin from 
its cargoes [348]. It was further found that tau mislocalises 
the kinesin adapter-molecule C-Jun amino-terminal kinase 
(JNK)-interacting protein 1 away from microtubules and 
into the neuronal soma [225, 227]. Notably, a recent report 
has suggested that, at least in Drosophila, loss of tau results 
in inhibition of kinesin-driven axonal transport leading to 
the accumulation of synaptic proteins in the neuronal cell 
body and subsequent synaptic decay [496]. The molecu-
lar mechanism underlying the functional deficit appears 
to be mediated by JNK activation caused by microtubule 
instability upon loss of tau function [496]. Consequently, 
pathological tau cannot only compromise the structural 
basis of synapses, but also inhibit transport of other car-
goes to the synapse, resulting in synaptic degeneration. In 
such a scenario, displaced organelles, such as mitochondria 
may accumulate in the neuronal soma, resulting in energy 
deprivation and oxidative stress which fuels the progres-
sion of pathology and neuronal demise in AD and related 
disorders.
Nuclear tau dysfunction
Key events involved in nuclear tau dysfunction include 
tau mutation, tau abnormal phosphorylation and oxida-
tive stress. In fibroblasts and lymphocytes from FTLD-tau 
affected patients, a series of cell deficits are observed in 
cells bearing tau mutants, including increased suscepti-
bility of the cells to stress, altered gene transcription, and 
chromosome aberrations [421, 422]. In contrast, the impact 
of phosphorylation on the nuclear function of tau is more 
complex. On one hand, there is evidence showing that 
abnormal phosphorylation of tau, such as is apparent in 
human tauopathies, reduces the nuclear translocation of tau 
[282] and the ability of tau to bind and protect DNA [61, 
312, 403]. These results suggest a detrimental loss-of-func-
tion of nuclear tau upon its increased phosphorylation. The 
absence of nuclear tau enhances oxidative stress-induced 
DNA and/or chromosomal damage. However, a gain of 
toxic function for highly phosphorylated tau in the nucleus 
cannot be excluded. It has been suggested that increased tau 
phosphorylation lies upstream of oxidative stress-induced 
DNA strand breakage [139, 344, 494]. Moreover, accu-
mulation of phosphorylated tau in the nucleus triggered by 
Aβ exposure and by viral infection has also been suggested 
[344]. Phosphorylated tau in the nucleus may be recruited 
to stress granules by TIA1, altering granule dynamics and 
sensitising cells to stress [53]. Downstream, the outcome 
of nuclear tau dysfunction in disease could include (1) dis-
rupted heterochromatin organisation, leading to cell cycle 
re-entry which is fatal to neurons [446], and (2) dysregu-
lated gene expression and rRNA synthesis, giving rise to 
altered protein synthesis [139, 199]. Notably, tau aggre-
gates have also been found in the nucleus in affected neu-
rons in Huntington’s disease, FTLD-tau, and AD [128, 130, 
335]. However, the consequences of harbouring aggregated 
tau in the nucleus in relation to tauopathy, await further 
investigation.
Dendritic tau in the tauopathies
A few reports have highlighted a gain of toxicity of den-
dritic tau in promoting neurodegeneration under patho-
logical conditions [80]. Ittner and colleagues showed that 
dendritic tau mediates Aβ toxicity by targeting the non-
receptor-associated tyrosine kinase Fyn, to post-synaptic 
N-methyl-d-aspartate receptors (NMDARs) in mouse brain 
[226]. Fyn kinase then phosphorylates the NR2B subunit 
of the NMDAR, rendering neurons susceptible to excito-
toxicity mediated by Aβ [361, 413, 420]. Furthermore, tau 
directly binds to Fyn [273, 276, 483]. Both trafficking of 
Fyn into post-synaptic sites in dendrites and stress-induced 
dendritic atrophy are abolished in tau knockout mice [226, 
310]. Dendritic tau has also been shown to form a com-
plex with post-synaptic density (PSD)-95, suggesting that 
tau can act as a synaptic scaffolding protein [67, 226, 345]. 
However, this notion is controversial because interactions 
between tau and PSD-95 can be protective [360]. Exposure 
to Aβ results in tau mislocalisation to the somatodendritic 
compartment, mediates AMPA receptor signalling deficits 
in  APPswe-transgenic mice, which express the familial AD-
associated APP mutation KM670/671NL [338].  APPswe 
mice exhibit enhanced Aβ production and the formation of 
amyloid plaques along with cognitive deficits [209]. There 
is also evidence that in rTg4510 mice, mislocalised den-
dritic tau is sufficient to perturb AMPA and NMDA recep-
tor signalling, leading to synaptic dysfunction [205].
Another route through which dendritic tau can exert 
toxicity relates to the interplay between tau and the micro-
tubule severing enzymes, katanin and spastin, both of 
which induce microtubule depolymerisation [326]. The 
presence of tau in axons protects microtubules from sev-
ering by katanin. In contrast, dendritic tau recruits tubulin 
tyrosine ligase-like 6 (TTLL6), causing it to mislocalise 
to dendrites, where it polyglutamylates the microtubules, 
687Acta Neuropathol (2017) 133:665–704 
1 3
increasing their susceptibility to spastin cleavage [486, 
532]. Mislocalisation of tau in dendrites results in the loss 
of normal microtubule structure and deleterious effects on 
axonal transport [534]. Therefore, increased tau in den-
drites causes cargoes, such as mitochondria, vesicles, and 
neurofilaments that are normally transported between the 
somatodendritic and axonal compartments and nerve ter-
minals, to become mislocalised in affected neurons [532, 
534].
Although some components of the mechanism underly-
ing the toxicity of dendritic tau have been identified, the 
upstream events leading to tau missorting are less well 
understood. Several studies indicate that Aβ-induced tau 
mislocalisation is permissive for the deleterious effects of 
Aβ [67, 533, 535]. More recently, it has been shown that 
the physiological translocation of tau from dendrites to the 
post-synaptic density is reduced following Aβ exposure, 
resulting in tau accumulation in dendritic spines [136]. 
However, the finding of dendritic tau in AD brain regions 
that do not have significantly elevated Aβ [48] raises the 
question of whether tau mislocalisation is necessary and 
sufficient for Aβ toxicity [38, 80].
The accumulation of tau harbouring the FTLD-tau 
mutation P301L, in dendritic spines has led to speculation 
that tau mutations contribute, either directly or indirectly, 
to tau mislocalisation [205, 524]. Recently, a study using 
fluorescence recovery after photobleaching revealed that 
the axodendritic gradient distribution of tau is inverted by 
overexpression of either wild-type or mutant P301L tau, 
suggesting that the protein level of tau may also be a mod-
ulator of tau dendritic mislocalisation [523]. Several lines 
of evidence suggest an association between tau post-trans-
lational modifications and its somatodendritic redistribu-
tion [80]. Phosphorylation of tau within the KXGS motifs 
located within the microtubule binding domain dramati-
cally reduces the ability of tau to bind to microtubules [179, 
336], which could be one of the initial steps involved in tau 
mislocalisation, as described above. Correspondingly, acti-
vation of MARK or AMPK, both of which phosphorylate 
tau at KXGS motifs, is critical for the synaptotoxicity and 
dendritic spine abnormalities induced by Aβ [180, 318, 
530]. Phosphorylation in the proline-rich domain of tau, 
particularly at Ser202/Ser205, may also contribute to its 
dendritic localisation. In AD, mislocalised dendritic tau is 
phosphorylated at Ser202/Ser205 but not at either Ser396/
Ser404 or Thr231/Ser235 [234, 535]. Phosphorylation 
of Ser202/Ser205 is associated with activation of MARK 
and Cdk5 but not GSK3β. Conversely, pseudo-phospho-
rylated tau at Thr231/Ser235, Ser262/Ser356 and Ser396/
Ser404 markedly enhances the targeting of tau to spines 
[524]. Furthermore, newly synthesised tau is missorted to 
the somatodendritic compartment prior to its phosphoryla-
tion by MAPK [532]. Taken together, the link between tau 
phosphorylation and mislocalisation is evident, whereas the 
spatial and temporal relationship between these two events 
is yet to be established. Notably, tau acetylation should also 
be considered as being a putative factor in tau mislocalisa-
tion in neurons. Acetylated tau also has an impaired abil-
ity to bind to microtubules [83] and pseudo-acetylated tau 
has recently been found to missort into the somatodendritic 
compartment, which could be related to the observed per-
turbation of the axon initial segment cytoskeleton in the 
animal models of AD [195, 458].
Tau and mitochondrial dysfunction
Mitochondrial dysfunction has been suggested to play a 
critical role in the development of tauopathy [528]. Accu-
mulation of tau disrupts mitochondrial localisation in 
human tauopathy brain and in animal models of disease, 
such as those expressing tau mutations associated with 
FTD [97, 259]. For example, increased reactive oxygen 
species have been reported in transgenic P301L tau mice 
[97, 259]. Although overt effects on mitochondrial dynam-
ics have not been observed in neurons cultured from P301L 
tau knockin mice, expression of this tau mutation signifi-
cantly reduces the number of mitochondria in axons [417]. 
The findings in P301L tau knockin neurons of increased 
volumes of individual motile mitochondria, accompanied 
by decreased phosphorylation of endogenous tau, suggest 
a role for tau and tau phosphorylation in the regulation of 
mitochondrial function and/or biogenesis [417].
Further evidence in support of a role for tau in 
maintenance of mitochondrial function comes from 
studies of the relationship between tau and the mito-
chondrial fission protein, dynamin-related protein 1 
(Drp1). Interaction between Drp1 and phosphorylated 
tau increases fragmentation of mitochondria, resulting 
in mitochondrial deficiency in affected neurons [320]. 
Increased Drp1 and mitochondrial fragmentation have 
also been reported in mice overexpressing tau and 
GSK3β [415]. Conversely, reducing Drp1 expression 
decreases phosphorylated tau and reduces mitochon-
drial dysfunction in P301L tau over expressing mice 
[243]. In AD, there is evidence for both increased fis-
sion and decreased fusion of mitochondria, as well as 
enhanced interaction of Aβ with Drp1, impaired axonal 
transport of mitochondria, and synaptic degeneration 
[319].
Notably, several groups have demonstrated an asso-
ciation between mitochondria and an N-terminal tau frag-
ment  (Tau26–230), detected in cellular and animal models 
of AD, as well as in AD brain [8, 24, 404].  Tau26–230 is 
enriched in mitochondria prepared from AD brain, cor-
relating with synaptic and mitochondrial dysfunction [8]. 
 Tau26–230 is also associated with Parkin leading to increased 
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Parkin-dependent turnover of mitochondria, and neuronal 
death which could be partially restored by suppressing 
mitophagy [90]. A recent report has also indicated that 
tau truncated at Asp421 induces mitochondrial fragmenta-
tion possibly through a reduction in optic atrophy protein 
1 [389]. Increases in cytochrome c oxidase IV, translocase 
of outer mitochondrial membrane 20, and mitochondrial 
DNA, which are indicators of mitophagy, have also been 
detected in AD brain and in tau transgenic mice [210]. Fur-
thermore, overexpression of tau has recently been shown to 
result in defective mitophagy in neurons, along with accu-
mulation of tau in the outer mitochondrial membrane and 
consequent increases in mitochondrial membrane poten-
tial [210]. Taken together, these findings suggest that tau 
and Aβ significantly affect mitochondrial integrity and 
the maintenance and function of synapses in health and 
disease.
Tau clearance by the ubiquitin‑proteasome system 
and autophagic‑lysosomal degradation
Incomplete clearance from the brain of pathological tau 
could also result from its inefficient degradation through 
the UPS and/or autophagic-lysosomal system. The UPS 
mediates the selective degradation of nuclear and cyto-
solic proteins, whereas the autophagy-lysosomal system 
is primarily involved in the clearance of long-lived pro-
teins and organelles through non-selective bulk degrada-
tion [424].
Several studies have demonstrated that tau can be 
degraded through the UPS and by the autophagic-lyso-
somal system. Identification of ubiquitination sites on 
both soluble and insoluble highly phosphorylated tau has 
provided a strong evidence for the role of the UPS in tau 
clearance [279]. Moreover, unfolded tau is proposed to be 
processed independent of ubiquitination [98].The signifi-
cance of the UPS in tau clearance is further supported by 
the identification of UPS components, such as heat shock 
protein 27 and CHIP as tau binding partners [279]. Thus, 
it is not surprising that dysfunction of the UPS is observed 
in a number of tauopathy models and in AD [107, 359]. 
Phosphorylated tau aggregates bind to the 20S subunit of 
the proteasome and this could interfere with tau degrada-
tion by inhibiting proteasomal activity [249]. Although it 
has not yet been established whether damage to the UPS 
precedes or is induced by tau aggregate formation, manipu-
lation of the UPS may be a potential treatment strategy in 
the tauopathies. For example, activating the 26S protea-
some via the cAMP-PKA pathway enhances tau degrada-
tion and rescues the damaging effects of tau oligomers on 
UPS activity [308, 359]. In contrast, the results of target-
ing the HSP response are more variable possibly due to the 
differential selectivity of HSPs. Thus, induction of HSP70 
reduces tau aggregation [117, 392], whereas inhibiting 
HSP90 yields similar beneficial effects [111, 314]. In both 
cases, the role of CHIP is pivotal for tau degradation [392, 
452].
Whereas soluble tau is preferentially degraded by the 
proteasome, pathological forms of phosphorylated tau 
appear to be directed towards to the autophagic-lysosomal 
system for disposal. Indeed, direct evidence for autophagy 
as the primary route for clearing phosphorylated, but not 
endogenous, tau has been obtained from monitoring the dif-
ferential degradation rates of phosphomimic tau mutants, 
wild-type tau and endogenous tau in neurons [264, 416]. 
It is not unreasonable to propose that malfunction of the 
autophagic-lysosomal system could contribute to the devel-
opment of tauopathy. Indeed, impaired autophagy has been 
repeatedly reported in tau-mediated neurodegenerative dis-
eases. For example, accumulation of immature autophagic 
structures and intermediates, such as autophagosomes and 
late autophagic vacuoles, has been observed in dystrophic 
neurites in AD brain, and in animal and cell models of 
AD, suggesting impaired degradation of autophagic vacu-
oles by lysosomes [303, 367, 471]. Additional evidence of 
a role for autophagy in AD comes from the colocalisation 
in neuronal and glial cells of Alz-50 antibody immunoreac-
tivity, an early indicator of tau misfolding with lysosomes 
[217, 218]. Furthermore, both inhibition of autophagosome 
formation and perturbation in lysosomal function, were 
found to account for delayed degradation of tau, enabling 
its accumulation in human neuroblastoma cells and trans-
genic mice [42, 186]. Stimulating mTOR activity, which 
represses autophagy, also increases total and phosphoryl-
ated tau in P301S tau mice [56]. Autophagy deficiency 
also results in the formation of intracellular inclusions of 
phosphorylated tau in autophagy-related protein 7 (Atg7) 
knockout mice [219]. Moreover, genetic ablation of cath-
epsin D enhances neurotoxicity and reduces lifespan of 
Drosophila [31, 252]. In contrast, stimulation of autophagy 
promotes tau clearance, reduces tau aggregation and cyto-
toxicity, and rescues neurodegeneration [32, 85].
Tau fragmentation also impacts on tau degradation. 
Expression of N-terminally truncated tau in Tau35 mice 
is associated with dysfunction of autophagy/lysosomal 
degradation [42], and caspase-3-mediated truncation of 
tau at Asp421 enhances autophagic rather than protea-
somal degradation of tau [116]. When expressed in N2a 
cells,  tauRDΔK280, the repeat domain of tau with a K280 
deletion, which itself has a propensity to aggregate, was 
degraded by autophagy generating highly aggregation-
prone products [512].
The mechanisms underlying the preferential degrada-
tion of pathological forms of tau by autophagy are unclear, 
although highly phosphorylated and truncated tau is both 
susceptible to aggregation. Accumulation of tau oligomers 
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could exceed the capacity of the UPS to clear them from 
neurons or the UPS could be directly inhibited by disease-
associated tau aggregates [249]. Tau cleavage may also 
remove its polyubiquitination site which would prevent or 
limit clearance by the UPS and could expose motifs in tau 
that are targeted by chaperone-mediated autophagy [82, 
512]. Impaired autophagy, due to defective microtubule-
associated autophagic vacuoles, could also result in p62/
SQSTM1 accumulation which might sequester other pro-
teins required for proteasomal degradation [40, 303]. Col-
lectively, these findings serve to highlight the pivotal role 
of autophagy in disease pathogenesis in the tauopathies, 
and suggest that restoration of efficient lysosomal proteoly-
sis and autophagy offer a promising therapeutic strategy.
The unfolded protein response and tauopathy
The unfolded protein response (UPR) is elicited by the 
endoplasmic reticulum (ER) to internal and external 
insults, including protein misfolding. Initiation of the 
UPR results in signalling through three branches, each of 
which utilises one of the three ER stress sensors: inositol-
requiring transmembrane kinase/endonuclease 1 (IRE1), 
activating transcription factor 6 (ATF6), or (PKR)-like 
endoplasmic reticulum kinase (PERK) [437]. Initiation 
of the UPR then triggers signalling cascades, which lead 
to different outcomes, depending on the signalling branch 
activated. For example, activation of IRE1 initiates the 
splicing of X-box binding protein 1 (XBP1) mRNA, lead-
ing to a frame-shift and expression of spliced X-box-
binding protein 1 (sXBP1), which drives transcription of 
genes including ER chaperones which facilitate protein 
folding in the ER [419, 447]. PERK is a transmembrane 
protein kinase that phosphorylates and activates eukary-
otic initiation factor 2α (eIF2α). Activated eIF2α blocks 
the loading of mRNA to ribosomes during the initiation 
of transcription, leading to reduced protein synthesis 
[126] and preferential translation of activating transcrip-
tion factor (ATF) 4. In parallel, UPR activation causes 
the cytoplasmic domain of ATF6 to be released from the 
ER, cleaved and translocated to the nucleus. Ultimately, 
these ATFs modulate the expression of an array of genes 
governing ER protein folding capacity, autophagy, redox 
control, amino acid metabolism, and apoptosis, including 
CCAAT-enhancer-binding protein homologous protein 
(CHOP) [200].
Accumulating evidence from genetic and biochemical 
studies has shown that the UPR is activated at early stages 
in tauopathy brain [206, 366, 482]. UPR activation has 
also been implicated in cell and animal models of tauopa-
thy, as well as in torpor, a physiological in vivo model of 
hypometabolism [487], although the means by which tau 
contributes to the activation of the UPR remains unknown. 
Accumulation of P301L tau in transfected HEK cells facili-
tates the interaction of tau with ER membrane and with 
proteins essential for ER-associated degradation (ERAD), 
resulting in UPR activation [2]. In JNPL3 mice, accumula-
tion of transgenically expressed P301L tau in the rough ER 
increases its contacts with mitochondria which may poten-
tially disrupt calcium homeostasis [390]. Indirect mecha-
nisms, such as generation of reactive oxygen species and 
impaired protein degradation caused by microtubule dis-
organisation may also contribute to UPR activation [303]. 
In vitro induction of ER stress also correlates with Aβ oli-
gomer-induced tau phosphorylation [409].
Several studies have highlighted the role of GSK3β-
mediated tau phosphorylation in UPR activation and tauop-
athy progression. In AD brain, increases in UPR markers 
closely correlate with the presence of phosphorylated tau 
and GSK3β [366]. In AD hippocampal neurons harbouring 
abnormally phosphorylated tau, phospho-PERK colocalises 
with both GSK3β and phosphorylated tau [207]. Activa-
tion of PERK facilitates P301L tau phosphorylation, which 
is reduced by a PERK inhibitor in rTg4510 mice [405]. 
Induction of the UPR in HepG2 and SHY-SY5Y cells also 
correlates with increased activity of GSK3β [253, 460]. 
Correspondingly, inhibiting GSK3β with lithium chloride 
protects tau from the increase in phosphorylation induced 
by thapsigargin, both in vitro and in rat brain [142]. Fur-
thermore, it has been suggested that there may be a vicious 
cycle wherein UPR activation contributes to tau phos-
phorylation and that increased tau phosphorylation also 
activates the UPR. Elevations in active PERK and eIF2α, 
splicing of XBP1 mRNA, and elevated CHOP mRNA have 
been found in primary neurons treated with the protein 
phosphatase inhibitor, okadaic acid, which also increases 
tau phosphorylation [202]. Increasing the expression of 
selenoprotein S, a component of an ER membrane complex 
that removes misfolded proteins from the ER decreases tau 
phosphorylation induced by ER stress [425]. Initiation of 
the UPR can enhance GSK3β-mediated tau phosphoryla-
tion through different mechanisms. First, activated UPR 
sensors, particularly IRE1 and PERK, can either inhibit Akt 
or suppress insulin-induced inhibition of GSK3β, leading to 
increased GSK3β activity [133, 305]. Second, the ER-asso-
ciated chaperone, binding immunoglobulin protein (BiP), 
which is elevated by UPR activation, facilitates tau phos-
phorylation through enhancing the association of GSK3β 
with tau [305]. Overexpression of SIL1, a co-chaperone 
of binding immunoglobulin protein (BiP), significantly 
reduces tau phosphorylation induced by elevated expres-
sion of BiP or thapsigargin treatment [304]. Finally, UPR 
activation increases the activity of GSK3 in vitro by selec-
tive removal of inactive GSK3 [365]. Inactive GSK3 also 
accumulates in lysosomes in tauopathy brain. Addition-
ally, activation of the UPR and induction of eIF2α activity 
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could contribute to neurodegeneration by repressing global 
protein translation, potentially attenuating the synthesis of 
several key synaptic proteins leading to synapse dysfunc-
tion and cognitive decline. In support of this speculation, 
the hippocampal amounts of the GluR2, AMPA receptor 
subunit, PSD-95, and synapsin-1, all decreased following 
tunicamycin-induced UPR activation in rats [291]. Collec-
tively, these findings indicate that modulation of the UPR, 
particularly the PERK/eIF2α signalling branch, may exert a 
dual beneficial effect in the tauopathies, not only by restor-
ing vital protein synthesis in compromised neurons, but 
also by decreasing tau phosphorylation.
Tau seeding and propagation
A key characteristic of prion-like protein transmission 
is that of intercellular propagation, which results in the 
spread of disease-related protein aggregates across the 
brain [137, 402]. Tau has been described as having prion-
like properties because in P301L tau transgenic mice, 
in which tau expression was restricted primarily to the 
entorhinal cortex, misfolded tau spreads from the entorhi-
nal cortex into the CA1 region of the hippocampus and 
granule cells of the dentate gyrus [103, 302]. Tau aggre-
gation and synaptic degeneration were observed in neu-
rons lacking detectable expression of P301L tau. Thus, 
the mutant transgenic tau-induced deleterious aggrega-
tion of both endogenous wild-type and transgenically 
expressed tau [103]. Subsequent studies have shown that 
injection of brain extracts from P301S tau transgenic 
mice or human tauopathy into the brains of mice over-
expressing wild-type human tau, results in tau aggrega-
tion not only around the injection site, but also in more 
distal, connected brain regions [4, 79]. These findings 
suggest that neuronal connectivity, rather than proximity, 
is important for the spread of tau pathology. As well as 
demonstrating the ability of tau to undergo “prion-like” 
propagation from an initial restricted source, these stud-
ies also imply that pathological forms of tau are trans-
mitted trans-synaptically. Further evidence in support of 
tau trans-synaptic propagation has been obtained from 
cell models. For example, tau aggregates released from 
HEK293 donor cells are taken up by hippocampus neu-
rons, and this process is significantly enhanced by the 
formation of presynaptic contacts between neurons [58]. 
There is also evidence showing that tau can be secreted, 
transmitted, and taken up through cellular structures 
other than synaptic connections, suggesting the existence 
of “trans-cellular” propagation pathways [103, 385].
Tau secretion may be mediated through several differ-
ent mechanisms, including unconventional secretion, ecto-
somal and exosomal release, and/or tunnelling nanotubes. 
Under physiological conditions, tau in cultured rat cortical 
neurons is released into the medium and stimulating neu-
ronal activity enhances release of tau, the bulk of which 
is non-vesicular through a calcium-dependent mechanism 
[398, 522]. Tau release from neurons occurs in the absence 
of cell death, indicating that under these conditions the 
presence of extracellular tau is not the result of neuronal 
dysfunction [398, 522]. Enhanced neuronal activity also 
increases the steady-state level of extracellular tau in brain 
interstitial fluid in wild-type mice [525]. Similarly, release 
of tau from both HEK293 cells inducibly expressing 2N4R 
tau, and differentiated induced pluripotent stem cell-derived 
human neurons expressing 3R tau, is mediated through an 
unconventional, temperature-dependent mechanism that is 
not associated with vesicle secretion [68]. In human neuro-
blastoma M1C cells inducibly expressing 0N4R tau, and in 
rTg4510 mice, secretion of tau is also mediated in part by 
exosomes which display a propensity to seed aggregation 
of endogenous tau [396, 429]. It appears that, although a 
small proportion of tau is released in exosomes and ecto-
somes [119, 429], the majority of tau released from neu-
rons under physiological conditions is not surrounded by a 
lipid envelope [397]. However, a recent study in P301S tau 
mice has shown that microglia-derived exosomes may be 
responsible for transduction of tau between neurons [22]. 
Recently, tunnelling nanotubes have been identified as 
another mechanism by which tau aggregates may be trans-
mitted through direct contact between neurons. Increased 
numbers of tunnelling nanotubes are detected on neurons 
following exposure to exogenous tau [472]. Tau release 
from neurons due to chaperone-dependent exocytosis has 
also been identified [135]. The presynaptic co-chaperone 
cysteine string protein-alpha (CSPα) is involved in the 
release of several aggregated proteins associated with neu-
rodegenerative disease through a non-canonical exocytosis 
pathway [135], and CSPα is also dysregulated in AD [477]. 
Interestingly, both knockout of CSPα and increased protea-
somal degradation of CSPα, result in neurodegeneration 
in vivo suggesting that CSPα may have a protective role 
[430, 448, 449].
The concept of extracellular tau suggests additional 
roles for aggregated tau, which may be dependent on its 
uptake by adjacent and/or connected neurons. Low molecu-
lar weight aggregates and short fibrils of recombinant tau 
can be internalised by endocytosis [521]. Furthermore, 
extracellular AD brain-derived tau aggregates have been 
reported to be endocytosed by both HEK293T non-neu-
ronal cells and SHSY5Y human neuroblastoma cells [140, 
434]. In cultured cell lines, primary neurons and wild-type 
mice, extracellular tau attaches to heparan sulfate proteo-
glycans (HSPGs) and thereby enter cells by micropino-
cytosis [140]. This mechanism is shared with α-synuclein 
but not with huntingtin, fibrils, possibly because both tau 
and α-synuclein contain heparin/heparan sulfate-binding 
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domains which are required for HSPG binding [203]. In 
addition, Bin1, which increases the risk of developing late-
onset AD and modulates tau pathology, affects tau propa-
gation by negatively influencing endocytic flux [70, 246]. 
Thus, depletion of neuronal Bin1 enhances the accumu-
lation of tau aggregates in endosomes [59]. Conversely, 
blocking endocytosis by inhibiting dynamin reduces the 
propagation of tau pathology [521].
Certain structural changes in tau, such as fragmentation 
and/or oligomerisation, appear to enhance the ability of tau 
both to aggregate and to propagate between cells. C-ter-
minally truncated tau is abundant in synaptic terminals in 
aged control and AD brain [459]. Notably, depolarisation 
significantly potentiates tau release in AD nerve termi-
nals compared to aged controls, indicating that tau cleav-
age may facilitate tau secretion and propagation from the 
presynaptic compartment [459]. When expressed in SH-
SY5Y cells, the  Tau243–441 (Tau-CTF24) fragment showed a 
higher propensity for aggregation than full-length tau, fol-
lowing exposure to extracellular insoluble tau seeds [327]. 
 Tau243–441 inclusions from SH-SY5Y cell lysates also prop-
agated more efficiently than inclusions generated from full-
length tau [327]. Furthermore,  Tau243–441 aggregates bound 
to cells more rapidly and in greater amount than aggregated 
full-length tau [327]. These results suggest that truncation 
of tau enhances its prion-like propagation and likely con-
tributes to neurodegeneration.
Small tau oligomers have been suggested to be the 
major tau species undergoing tau propagation. Whereas 
oligomeric tau and short filaments of recombinant tau are 
taken up by primary neurons, tau monomers and long tau 
filaments purified from rTg4510 mouse brain are excluded 
[521]. Tau dimers and trimers isolated from PSP brain 
have also been shown to seed aggregation of 3R and 4R 
tau [157]. Notably, tau trimers also represent the minimal 
particle size that can be taken up and used as a conforma-
tional template for intracellular tau aggregation in human 
tau-expressing HEK293 cells [342]. In contrast, identifi-
cation of the seeding-competent tau species in P301S tau 
transgenic mice revealed the requirement for large tau 
aggregates (>10 mers) [228]. However, there appear to be 
biochemical differences between aggregates formed from 
recombinant tau and inclusions isolated from P301S tau 
mice. Thus, recombinant tau aggregates are more resistant 
to disaggregation by guanidine hydrochloride and digestion 
by proteinase K, and display a lower seeding potency than 
those from P301S tau mice [350, 434]. These studies high-
light the fact that the seeding competency of tau aggregates 
is dependent on both their size and conformation. It is clear 
that a balance between transmissibility and propensity to 
aggregate is required for effective inter-neuronal propaga-
tion of pathogenic tau species and resultant neurodegenera-
tion [432].
An interesting aspect of the transmissibility of prions 
is the fact that different strains of prions induce distinct 
neurodegenerative phenotypes with reproducible patterns 
of neuropathology [245]. Tau exhibits a similar behaviour 
when brain homogenates prepared from different types of 
tauopathy, including AD, PSP and CBD, are injected into 
the brains of transgenic ALZ17 mice which overexpress 
2N4R human tau [245]. The tau inclusions formed in the 
brain of injected ALZ17 mice closely resemble those in the 
originating source of brain extract. These findings support 
the view that during propagation tau forms multiple, stably 
propagating conformers with significant conformational 
and structural diversity. Fibrils formed of wild-type tau and 
mutant P301L/V337 M tau each have distinct secondary 
structures and morphologies [141]. Furthermore, wild-type 
tau aggregates induced by P301L/V337M tau seeds more 
closely resemble P301L/V337M fibrils than wild-type tau 
fibrils, and these are stable after repeated seeding [141]. 
Therefore, it appears that the nature of the tau seed is the 
determinant of the structural characteristics of the result-
ant tau aggregates [141]. This notion is further supported 
by the identification of two tau strains that induced distinct 
pathologies in cells and in vivo, each of which was passed 
on to daughter cells with remarkable fidelity [432]. In par-
allel, tau aggregates purified from AD or CBD brain also 
induce characteristic patterns of tau pathology in P301S 
tau mice [41]. The human tauopathy-derived aggregates 
affect different neural cell populations and distinct brain 
regions in the tau mice, suggesting that there may be addi-
tional parameters that discriminate between the tauopa-
thies in different tau prion strains. In a recent study, 18 tau 
strains isolated from recombinant tau fibrils, mouse brain, 
and human brain, were found to display differing intracel-
lular morphologies [245]. When injected into PS19 mice 
overexpressing human 1N4R P301S tau, these tau strains 
displayed differing spreading rates and preferences for spe-
cific brain regions, leading to a varied range of neuronal 
and astrocytic pathologies [245]. These results further rein-
force the idea that differences between tau strains account 
for the diverse biochemical and phenotypic manifestations 
of tauopathies.
Tau propagation can be further accelerated through acti-
vation of inflammatory pathways. Exposure of extracel-
lular misfolded truncated tau activates microglia through 
the MAPK pathway and induces the production of pro-
inflammatory cytokines, including Interleukin-1β, Interleu-
kin-6 and tumour necrosis factor alpha [263], which pro-
mote tau phosphorylation inside neurons [543]. Moreover, 
activated microglia may directly mediate tau propagation. 
The detection of tau in microglial-derived exosomes has 
demonstrated the involvement of microglia in tau propa-
gation [22]. Around the same time, microglial activation 
resulting from deficiency of microglia-specific fractalkine 
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receptor is found be preceding the spreading of tau pathol-
ogy between anatomically connected hippocampal regions. 
Taken together, these results suggest that neuroinflamma-
tion could induce, or at least facilitate the propagation of 
tau pathology. Conversely, evidence showing microglial 
degeneration caused by soluble phospho-tau from AD hip-
pocampi has also been reported [431]. Although the expo-
sure of extracellular tau seemed to result in two conflict-
ing outcomes, these findings are not naturally exclusive as 
the soluble fraction from AD hippocampi is consist of a 
mixture of tau species, which process different infectivity 
and cytotoxicity. It is also notable that the impact of neu-
roinflammation on tangle formation are rather limited and 
vice versa; no toxic effects of sarkosyl-insoluble tau on 
microglia was observed, providing peripheral evidence for 
the notion that more dynamic tau species are in the central 
stage during tau propagation [431, 543].
In summary, there is a significant body of evidence in 
support of the prion-like hypothesis for tau propagation, 
potentially through trans-synaptic transmission of patholog-
ical tau oligomers and/or aggregates [103, 302]. This could 
explain how the occurrence of an initial nidus of aggregated 
pathological tau may seed tau aggregation and then spread 
to more distal brain regions during the pathogenesis of 
tauopathy [162]. Meanwhile, a role of neuroinflammation in 
tau propagation has also been suggested shedding new light 
on potential therapeutic strategies. Furthermore, the discov-
ery of both soluble and oligomeric forms of extracellular 
tau offers a plausible explanation for the apparent efficacy 
of tau antibody immunisation to slow disease progression in 
mouse models of tauopathy [23, 37, 44, 69].
Tau targeted treatments
A variety of different therapeutic strategies have been 
examined for their efficacy in the tauopathies (reviewed in 
[172]). These approaches include reducing tau aggrega-
tion and/or preventing tau oligomer formation (reviewed 
in [52]). Small molecules that reduce tau aggregation in 
cell models and in transgenic mice, including methyl-
thioninium derivatives, and other compounds identified 
through chemical microarray and library screens, have 
yet to be shown to be effective in human disease. For 
example, a Phase III clinical trial of leuco-methylthionin-
ium bis(hydromethanesulfonate) (LMTM) has not shown 
benefit as an add-on treatment for mild-to-moderate AD 
[155]. However, it is possible that LMTM may yet prove 
to have some potential as a monotherapeutic agent and 
longer term clinical studies remain in progress to deter-
mine the efficacy of this tau disaggregating compound.
Previous clinical trials have targeted tau phosphoryla-
tion in AD and PSP by investigating inhibitors of the 
protein kinase GSK3. However, despite some of these 
compounds effectively reducing phosphorylated tau in 
CSF, none have shown efficacy in tauopathy [187]. A 
complementary approach is using MK-8719 (Alectos 
Therapeutics Inc, and Merck Sharpe and Dohme), an 
orally available small molecule, which selectively inhib-
its O-GlcNAcase, thereby potentially preventing phos-
phorylation at the same sites on tau. MK-8719 is desig-
nated as an orphan drug and a Phase I clinical trial for 
PSP has recently been completed, the outcome of which 
is awaited.
Alternative strategies to target tau include active immu-
nisation with tau polypeptides, or passive immunisation 
using antibodies recognising tau. Testing of active tau 
immunisation in Phase II clinical trials for mild-moderate 
AD (NCT02579252) is ongoing for AADvac1 (Axon Neu-
roscience SE), which comprises misfolded tau, residues 
294–305 (KDNIKHVPGGGS). An early obstacle to the 
implementation of tau antibody therapy was the supposition 
that antibodies would need to be internalised by neurons to 
be effective, and that immune modulation and microglial 
activation might also be problematic. Recently, however, 
it has become apparent that binding of antibodies to tau 
may be sufficient to alleviate the spread of tau pathology 
and potentially also disease pathogenesis [280]. Clinical 
trials of passive tau immunotherapy include the potentially 
therapeutic antibodies (1) ACI-35 (AC Immune SA and 
Janssen), which targets tau residues 393–408, phosphoryl-
ated at Ser396/Ser404 (VYKpSPVVSGDTpSPRHL), in a 
recently completed Phase Ib trial for mild-to-moderate AD, 
(2) C2N-8E12 (AbbVie and C2N Diagnostics), a human-
ised antibody that recognises residues 25–30 (DQGGYT) 
in aggregated tau, in Phase II trials for AD (NCT02880956) 
and PSP (NCT02985879), (3) BMS-986168 (Bristol-Myers 
Squibb), a humanised antibody targeting residues 9–18 
(EVMEDHAGTY) of extracellular N-terminally truncated 
tau, about to enter a Phase II trial for PSP (NCT03068468), 
and (4) RO7105705 (AC Immune SA, Genentech, and 
Hoffmann-La Roche) an antibody targeting phosphorylated 
Ser409 in tau, in a Phase I trial for mild-to-moderate AD 
(NCT02820896). It is not yet clear which form, or which 
precise sequence of tau will be the most suitable target for 
immunotherapy, however, this may become apparent once 
the results from current clinical trials are reported. If a 
safe and effective tau-based vaccine can be produced, this 
would offer the possibility of providing long-term protec-
tion against the development of tauopathy.
Concluding remarks
It is becoming clear that tau can undertake a multitude 
of roles beyond its most well established function of 
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stabilising axonal microtubules. Functions now ascribed 
to tau include maintaining structural integrity, axonal 
transport, and signalling within and between neurons. 
These roles are facilitated by the finding that tau is 
located not only in axons but is also found in multiple 
neuronal compartments and in the extracellular spaces.
An intriguing and still poorly understood aspect of tau 
biology is the rationale for the existence of six alternatively 
spliced tau isoforms in the adult human CNS. The bal-
ance of tau isoforms in human brain is clearly important, 
since disrupted tau splicing with a consequent alteration 
in the ratio of tau protein isoforms is apparent in several 
tauopathies. Changes in the 4R/3R tau isoform balance are 
directly linked to many of the known causal mutations in 
MAPT. However, the fact that the tau isoform ratio is also 
affected in sporadic disease, in which no mutations in tau 
have been detected shows that tau splicing is regulated by 
factors other than MAPT transcript expression. This sug-
gests the possibility of tau isoform-dependent degradation, 
which could be regulated by differential association of dis-
tinct tau isoforms with specific subcellular compartments 
or organelles. Maintaining a physiological balance of 
4R/3R tau isoforms clearly has important implications for 
the tauopathies, since this affects maintenance of the micro-
tubule cytoskeleton as well as having a potential impact on 
the association of tau with binding proteins and possible 
tau mislocalisation. It is important therefore to understand 
the biological importance of the expression of multiple 
spliced tau isoforms as well as the functions of each of the 
individual tau species. This knowledge may ultimately lead 
to identification of novel mechanisms involved in the devel-
opment of tau pathology and disease pathogenesis in the 
tauopathies.
Another pressing area in the field is to better under-
stand the functions of extracellular tau and the conse-
quences of both physiological tau release and pathologi-
cal tau propagation. The extrusion of soluble tau from 
neurons is a normal physiological event that is stimulated 
by neuronal activity. Furthermore, experiments in cell 
models have shown that tau aggregates can be taken up 
by and released from cells expressing aggregation-prone 
tau. The secretion and uptake of these different forms of 
soluble and insoluble tau most likely occur through dis-
tinct mechanisms. It is conceivable therefore that physi-
ological secretion and uptake of soluble tau may initiate 
a potentially receptor-mediated component of intercel-
lular signalling between neurons. In contrast, the release 
of aggregated tau is of particular interest in the tauopa-
thies, since this could represent an attempt to remove 
potentially pathogenic tau from affected neurons. Such 
extracellular tau aggregates can be taken up by con-
nected neurons, thereby providing a template for further 
misfolding of tau in unaffected neurons and resulting in 
the spreading of tau pathology. Discovering the temporal 
course of tau release and propagation during tauopathy 
development, and elucidating the molecular mechanisms 
underlying the release and uptake of both physiological 
and pathological forms of tau, are therefore important 
research goals.
There is increasing research interest in the involvement 
of tau in neurodegenerative disease, and the means by 
which new therapies can ameliorate tau-associated neuro-
degeneration. Therapeutic strategies aimed at reducing tau 
aggregation have not yet delivered the promise predicted 
from the results of experimental animal and cellular mod-
els. Moreover, this approach is complicated by the complex 
issue of whether highly aggregated forms of tau are toxic or 
protective to neurons. Thus, if tau tangles do provide some 
degree of neuroprotection, then disaggregating treatments 
could potentially exacerbate tauopathy through generat-
ing toxic, lower-order tau oligomers and soluble forms of 
phosphorylated tau. However, there is hope that clinical tri-
als of tau immunotherapies may yet prove to be successful. 
One of the most pressing issues with tau-directed antibody 
approaches is to identify the precise form of tau, including 
either a specific region of the protein, a post-translational 
modification, or a distinct tau conformation that might be 
most efficiently targeted using this approach. Nevertheless, 
even in the absence of this knowledge, it seems feasible 
that either passive or active immunisation which results in 
an overall reduction in the total amount of tau could prove 
effective in tauopathies.
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